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After heart disease, cancer is the leading cause of death in the U.S. According to the 
National Cancer Institute, approximately 38% of the population will be diagnosed with 
cancer at some point over the course of their life. This number is only expected to increase 
with the increased age of the general public due to medical progress, leading to an increased 
importance in finding effective and convenient treatment that can be used across a wide 
array of cancers. 
 
In theory, any tumor can be destroyed using enough of a cytotoxic method, whether it be 
heating, radiation, surgery, or chemotherapy. However, because cancer cells are derived 
from a person’s own healthy cells mutating, all of these treatments involve destroying 
healthy tissue in the process. Because of this, the most important aspect of any treatment 
modality is its tumor specificity: the ability of the treatment to target cancerous tissue vs. 
healthy tissue. The higher the ratio of cancer cell death to healthy cell death a treatment 
contains, the more effectively it can be used in clinical practice. 
 
A common method of targeting cancerous tissues is by targeting biomarkers that are 
overexpressed in cancer cells. These can include utilizing antibody, receptor, or vitamin 
bindings. While these methods can increase the specificity of treatment, there are also 
associated shortcomings with them. They tend to be cell-line specific, so a treatment that 
may work for one strain of cancer may not have the desired effect across other lines. Even 
within a single cancer strain, there exists heterogeneity a tumor, resulting in some cells not 
expressing the biomarkers to the extent needed for adequate targeting. This not only results 
 
 
in some cells surviving damage, but those cells then go on to reproduce, passing on their 
traits, and causing the tumor to adapt to become more resistant to that treatment. Within 
this arises the need to target a more general biomarker presented throughout all cancer cells 
and strains. 
 
In 1931, the Nobel Prize in Physiology was awarded to Dr. Otto Heinrich Warburg for his 
discovery of what is known as the Warburg effect. In his research, Dr. Warburg discovered 
that even in the presence of oxygen, cancerous tissue produces the majority of  its energy 
via anaerobic glycolysis instead of the aerobic oxidative phosphorylation. Glycolysis is a 
much less efficient, but faster, process, resulting in an excess of positively charged 
hydrogen ion byproducts. These are pumped outside of the cell membrane to maintain a 
normal pH within the cell, which results in a low pH environment immediately 
extracellularly to cancerous tissue. This acidity at the surface of cancer cells is ubiquitous 
across solid tumors, making it an ideal biomarker to target for cancer treatment. 
 
pH-Low Insertion Peptide (pHLIP) is a pH-dependent peptide, whose pH-dependent action 
is based on the protonation of the aspartic (Asp) and glutamic (Glu) acid residues at tge C-
terminal end of the peptide. In the presence of a low pH environment, the normally 
negatively charged Asp and Glu residues of pHLIP become protonated, increasing the 
overall hydrophobicity of the polypeptide. In the presence of a lipid bilayer, it triggers the 
insertion of the peptide across the bilayer to form a transmembrane alpha helix. Because 
of the Warburg effect described above, the acidity surrounding a cancerous tissue therefor 
promotes selective insertion of pHLIP across the cell membrane of tumor cells. As a result, 
 
 
different cargoes can be attached to the peptide, consequently being either tethered or 
translocated across membrane of cells in acidic diseased tissue at much higher proportions 
than in healthy tissue. 
 
The main goal of this work was to evaluate the efficacy of different pHLIP variants to 
target tumors and deliver cargo across the membrane for therapeutic and 
diagnostic/imaging applications. In therapeutic applications, the attached cargo would 
directly induce cell death via external radiation enhancement, cell heating, or radioactive 
emission. For this, gold nanoparticles (GNPs) were studied, as gold is an inert and 
biocompatible. The focus of this work was to create GNPs coated with pHLIP to allow for 
enhancement of radiation via Auger electron emission, and to explore the possibility of 
creating gold-coated bicelles for heating via plasmon resonance. For diagnostic and 
imaging applications, the attached cargo would be used to visually differentiate the 
cancerous and healthy tissue, and be used in coordination with therapeutic strategies such 
as surgery for treatment. For this, the near-infrared dye indocyanine green (ICG) was 
conjugated to pHLIP to make ICG-pHLIP. ICG is already used in clinics for fluorescence 
guided surgery for imaging of lymph nodes and blood flow, making ICG-pHLIPs transition 
to clinics more straightforward and efficient. The focus of this study was to find the ICG-
pHLIPs selectivity to cancerous tissue in vivo in balb-c and nude mice, exploring proof of 






I’d like to begin by expressing my utterly deepest gratitude to Dr. Yana Reshetnyak, who 
has helped me through countless mental breakdowns, rushed timelines, and some moments 
of crippling self-doubt. I applied to URI in engineering, and before I even began my college 
career, Yana had convinced me to join the physics department. The care and dedication she 
puts into her work and students was obvious even before I was lucky enough to have her 
advising me. She is responsible for both my decision to begin the doctorate path, and 
singlehandedly talked me into continuing it during some of my more stressful periods. I 
could not have gotten to this point without her, and I’ll never be able to convey the amount 
of appreciation I have for everything she has done for me. 
Secondly, I would be remiss if I spoke any less fondly of Dr. Anna Moshnikova. Without 
Anna, I truly believe my flaws would have come to light much quicker, and I don’t think 
my finishing would be possible without her. She has helped me through too many 
experiments to count, but to limit myself to talking about her direct help in the lab would 
be to do her a disservice. She has gone from being the mentor I’m terrif ied of disappointing, 
to a trusted colleague I can go to whenever I had questions, to a close friend I can come to 
whenever I have a problem of any kind, and somehow she’d always have the answer. 
During our countless hours working side by side, she has taught me how to become the 
best scientist I can be, and while I still have a lot to learn, at least I’ve learned some Russian 
to show for it (Mysh’ spit. I can (could?) also count to 10. After reconsidering, my Russian 
is not very good). Spasibo, Anna. 
vi 
 
In this physics department, I’d like to thank Dr. Leonard Kahn and Dr. Oleg Andreev 
specifically. Dr. Kahn has been someone who has guided me for nine years whenever I was 
uncertain about how to continue, and has always had my best interests at heart. It is rare to 
find someone as a freshman who not only pushes and believes in you, but that you can 
always share a laugh with on the side. Dr. Kahn has been all of that for me, and I will 
forever appreciate his understanding at my inability to navigate the red tape of grad school.  
Dr. Andreev has been a constant pressure to strive in my lab. Always pushing to get the 
best out of his students, his challenging and straightforward nature has always demanded 
the acquisition of more knowledge and understanding, as has stimulated me to b e the 
inquisitive and confident person I’ve become. 
Within my lab, there are two people I’d like to single out. Dr. Jenn Daniels, my mentor for 
my first two years of my grad school career, who helped me discover my general love of 
the lab work and research. I could not have asked for a better person to show me the ropes, 
and I swear, she did everything she could to teach me about the importance of organization 
and timeliness, my ineptitude in those areas are my own failure. It then flows into the next 
person, soon-to-be-Dr. Chip Slaybaugh, who has helped cover me through when that 
failure flared up. Every time I have forgotten to do something, left a machine on, or just 
had a problem too silly to explain to Anna, he has been there to help. It’s been great having 
someone to go through everything together with, and he’s been an irreplaceable presence 
in the lab. 
Beyond them, everyone in the lab has helped me through such an unbelievable amount of 
things. Anuradha, who has been a constant and helpful presence; Sean, who was incredibly 
fantastic to work with, teach, and learn from (and showed me how weird it is mentoring 
vii 
 
someone 3 inches taller than me); Ramona, who taught me the delicacies of mice work; 
Mike, who has been great at dealing with my inadequacies in teaching; Hannah, who’s 
always happy to have a scientific conversation where she shows me how little I really 
know; Linden, for showing me the professionalism we can express while still enjoying life 
beyond work; and Da, who showed me just how much I have to learn at guitar. Everyone 
in this list has been integral to my success at multiple points in my career.  
I’d like to thank my committee, Drs. Michael Anotsh, Geofferey Bothun, and Ying Sun. 
Quick and efficient communication has never been my strong suit, and they have worked 
with me through this entire process, and somehow despite all my shortcomings, I’m 
(planning on) graduating on time. I can only thank them earnestly for helping me schedule 
(with what must have seemed like supreme naïve incompetence) the impossible hour when 
four college professors are all free at the same time. 
Lastly, I’d like to thank my friends and family. Sean, Rob, and Wes, who have brought me 
through so many points in my life, and dealt with me every time I should have been 
intolerable. Elliott, Gus, and Ben, for distracting me with poker, football, and all things 
ridiculous. My parents, who have become more akin to incredibly close friends who just 
happen to have unwavering support of me despite all my failings. Gina and Tim, who have 
unintentionally worked together to teach me everything that’s important in life. Every 
single one of my friends who I couldn’t name because I honestly just don’t have enough 
room, I couldn’t have done this without all of you. 





This dissertation is written in “Manuscript” format, using the Thesis/Dissertation template 
of the University of Rhode Island. There are three manuscripts included in this dissertation, 
each of which comprises a chapter. The tables and figures of each manuscript are listed 
under the corresponding chapter in the list of tables and figures. 
 
The results of our studies presented in the first two chapters were published in the following 
papers: 
1. Wyatt L, Moshnikova A, Crawford TM, Engelman DM, Andreev OA, Reshetnyak 
YK. New pHLIPs for the Targeted Intracellular Delivery of Cargo Molecules to 
Tumors. PNAS (2018) 
2. Daniels JL, Crawford TM, Andreev OA, and Reshetnyak YK. Synthesis and 
Characterization of pHLIP® Coated Gold Nanoparticles. Biochem Biophys Rep 
(2017) 
The final chapter is composed of research that has been submitted for publication: 
3. Crawford TM, Moshnikova A, Roles S, Weerakkody D, DuPont M, Carter LM, 
Shen J, Engelman D, Lewis JS, Andreev OA, Rehestnyak YK. ICG pHLIP: A 










TABLE OF CONTENTS.........................................................................................ix 
LIST OF TABLES ...................................................................................................x 
LIST OF FIGURES.................................................................................................xi 
CHAPTER 1 ............................................................................................................1 
New pHLIPs for the Targeted Intracellular Delivery of Cargo Molecules to Tumors .......... 1 
CHAPTER 2 ..........................................................................................................36 
Synthesis and Characterization of pHLIP Coated Gold Nanoparticles............................ 36 
CHAPTER 3 ..........................................................................................................72 




LIST OF TABLES 
 
CHAPTER 1 
Table 1. List of peptide sequences.......................................................................... 30 
Table 2. Biophysical and cytotoxicity parameters of pHLIP variants ....................... 31 
 
CHAPTER 2 
There are no tables in Chapter 2 
 
CHAPTER 3 
Table S1. Qualification of GLP ICG-pHLIP batch #1912127 ................................ 139 
Table S2. Bound and unbound fractions of ICG-pHLIP ........................................ 141 
Table S3. Concentration of ICG-pHLIP in blood of mice and dogs ....................... 142 
Table S4. Fluorescence intensity in ex vivo imaging of organs .............................. 143 





LIST OF FIGURES 
 
CHAPTER 1 
Figure 1. Chemical structures and results of biophysical experiments with pHLIP  
bundles ................................................................................................................. 32 
Figure 2. Ellipticity ratios of CD signals for all pHLIP variants and therapeutic indices of 
pHLIP amanitin constructs .................................................................................... 33 
Figure 3. pH-dependent potency observed in in vitro experiments ........................... 34 




Figure 1. Characterization of spherical gold nanoparticles....................................... 68 
Figure 2. Structure of bicelles ................................................................................ 69 
Figure 3. Characterization of multispiked gold nanoparticles .................................. 70 
Figure 4. Tumor imaging of spherical gold nanoparticle uptake .............................. 71 
 
CHAPTER   3 
Figure 1. Characterization of ICG-pHLIP and blood clearance in mice and dogs ..... 96 
Figure 2. Imaging of blood vessels in mice............................................................. 97 
Figure 3. Imaging of blood vessels in pigs .............................................................. 98 
Figure 4. Biodistribution and Kinetics .................................................................... 99 
Figure 5. Tumor targeting .................................................................................... 100 
Figure 6. Ex vivo imaging of tumors with surrounding muscle .............................. 101 
xii 
 
Figure 7. Ex vivo imaging and imaging of section ................................................. 102 
Figure 8. Surgical removal of tumors under fluorescence guidance ....................... 103 
Figure S1. HPLC and MS of ICG-pHLIP ............................................................. 148 
Figure S2. ICG-pHLIP and Isosulfan Blue ........................................................... 149 
Figure S3. Inhibition response curves................................................................... 150 
Figure S4. Fluorescence angiography in mice ....................................................... 151 
Figure S5. Imaging of blood vessels in pigs.......................................................... 152 
Figure S6. ICG-pHLIP fluorescence in mice ........................................................ 153 
Figure S7. Tissue/Organ mean fluorescence values............................................... 154 
Figure S8. ICG-pHLIP fluorescence in human and murine tumors in mice ............ 155 






Published in PNAS in March, 2018 
 
New pHLIPs for the Targeted Intracellular Delivery of 
Cargo Molecules to Tumors 
 
Linden C. Wyatta, Anna Moshnikovaa, Troy Crawforda, 
Donald M. Engelmanb,1, Oleg A. Andreeva,1, Yana K. Reshetnyaka,1 
 
a Physics Department, University of Rhode Island, Kingston, RI 02881; 
b Department of Molecular Biophysics and Biochemistry, Yale, New Haven, CT 06511 
 
1To whom correspondence may be addressed. Emails: reshetnyak@uri.edu or 
andreev@uri.edu or donald.engelman@yale.edu 
 
Keywords: membrane-associated folding, tumor acidity, cytoplasmic drug delivery, polar 





Conflict of Interest Statement: D.M.E., O.A.A., and Y.K.R. are founders of pHLIP, Inc. 
They have shares in the company, but the company did not fund any part of the work 
reported in the paper, which was done in their academic laboratories. 
 
Abstract 
The pH (low) insertion peptides (pHLIPs) target acidity at the surfaces of cancer cells and 
show utility in a wide range of applications, including tumor imaging and intracellular 
delivery of therapeutic agents. Here we report pHLIP constructs that significantly improve 
the targeted delivery of agents into tumor cells. The investigated constructs include pHLIP 
bundles (conjugates consisting of two or four pHLIP peptides linked by polyethylene 
glycol) and Var3 pHLIPs containing either the nonstandard amino acid, γ-carboxyglutamic 
acid, or a glycine−leucine−leucine motif. The performance of the constructs in vitro and in 
vivo was compared with previous pHLIP variants. A wide range of experiments was per- 
formed on nine constructs including (i) biophysical measurements using steady-state and 
kinetic fluorescence, circular dichroism, and oriented circular dichroism to study the pH-
dependent insertion of pHLIP variants across the membrane lipid bilayer; (ii) cell viability 
assays to gauge the pH-dependent potency of peptide-toxin constructs by assessing the 
intracellular delivery of the polar, cell- impermeable cargo molecule amanitin at 
physiological and low pH (pH 7.4 and 6.0, respectively); and (iii) tumor targeting and 
biodistribution measurements using fluorophore-peptide conjugates in a breast cancer 
mouse model. The main principles of the design of pHLIP variants for a range of medical 





The targeted delivery of drugs to cancer cells promises to maximize their therapeutic 
effects while reducing side effects. Although many biomarkers exist that can be exploited 
to improve tumor targeting and treatment outcomes, such as various receptors 
overexpressed at the surfaces of some cancer cells, useful markers are not present in all 
tumors. Further, the heterogeneity of the cancer cell population in an individual tumor and 
between tumors of various patients limits the effective use of biomarker targeting 
technologies, and rapid mutation increases the likelihood of the selection of cancer cell 
phenotypes that do not express high levels of the targeted biomarker. Thus, biomarker 
targeting can act as a selection method that may lead to the development of drug resistance 
and poor patient outcomes (1–3). 
It is well known that acidosis is ubiquitous in tumors, including both primary tumors and 
metastases, as a consequence of their rapid metabolism (4). The acidic microenvironment 
is generated by the increased use of glycolysis by cancer cells, and by the ab undance of 
carbonic anhydrase proteins on the cancer cell surfaces. Tumor cells stabilize their 
cytoplasmic pH by exporting the acidity to the extracellular environment. As a result of the 
flux and the membrane potential, the extracellular pH is lowest at the surfaces of cancer 
cells, where it is significantly lower than normal physiological pH and the bulk 
extracellular pH in tumors (5–7). The low pH region persists at the cancer cell surface even 
in well-perfused tumor areas. The acidity on the surfaces of cancer cells is a targetable 
characteristic that is not subject to clonal selection, and the level of acidity is a predictor of 
tumor invasion and aggression, since more rapidly growing tumor cells are more acidic. 
The emerging technology based on pH (low) insertion peptides (pHLIPs) comprises a 
variety of acidity-targeting peptides, each possessing different tumor-targeting 




to have a range of options for specific applications. Some examples of these applications 
include (i) fluorescence imaging (8–10) and fluorescence image-guided surgery (11); (ii) 
nuclear imaging including PET and SPECT (single-photon emission computed 
tomography) (12, 13); (iii) therapeutic applications such as the targeted delivery of polar 
toxins that cannot cross cell membranes (14, 15), drug-like molecules that inherently 
diffuse across cell membranes (16, 17), and gene therapy (18); and (iv) nanotechnology for 
enhancing the delivery of gold nanoparticles (19, 20) or liposome-encapsulated payloads 
to cancer cells (21). 
The pHLIPs are triggered to insert across the membranes of cancer cells by the acidity at 
the cancer cell surface. The behavior of peptides in the pHLIP family is typically described 
in terms of three states: at physiological pH (pH 7.4), peptides exist in equilibrium between 
a solvated state (state I) and a membrane- adsorbed state (state II); a decrease in pH shifts 
the equilibrium toward a membrane-inserted state (state III) (22). The mechanism 
Results 
pHLIP constructs. We investigated nine pHLIP variants; among them are Var3/Gla (with 
nonstandard amino acid Gla), Var3/GLL (with glycine−leucine−leucine motif), and pHLIP 
bundles (Table 1). The pHLIP bundles consist of two- or four- armed polyethylene glycol 
(PEG) 2-kDa spacers conjugated to the cysteine residue at the N terminus of WT: PEG-
2WT and PEG-4WT, respectively (Fig. 1 A and B). Our motivation is to increase both the 
membrane affinity and the cooperativity of the transition from the membrane-surface state 
to the membrane- inserted state. Enhancement of affinity is expected to improve targeting, 
and higher cooperativity should narrow the window of pH that produces TM drug delivery. 
The information about all pHLIP variants used in the study with additional variations from 
the addition of single N- or C-terminal cysteine or lysine residues for conjugation purposes 




ways by shared characteristics. A WT-like group contains peptides with two protonatable 
residues (shown in bold in Table 1) in the putative TM region, multiple protonatable 
residues in the membrane-inserting C-terminal region, and two tryptophan residues 
(residue W) both located at the beginning of the helix- forming TM region; this group 
includes WT, PEG-2WT and PEG-4WT, WT/Gla, and WT/Gla/Aad. A Var3-like group is 
based on Var3 from the first pHLIP series (25). This group includes Var3, Var3/Gla, and 
Var3/GLL, each of which have three protonatable residues in the TM region and 
tryptophan residues located at the beginning and end of the TM region. Considering this 
scheme, ATRAM, with its multiple glycine and leucine residues and single tryptophan 
located about two-thirds to the end of its TM part, is in a group of its own. Other subgroups 
can be considered as well: a subgroup of peptides that incorporate the nonstandard Gla 
residue, shown in italics in Table 1 (i.e., WT/Gla, WT/Gla/Aad, and Var3/Gla), and another 
subgroup that includes peptides containing the GLL motif (Var3/GLL and ATRAM). 
When performing analysis of biophysical measurements, analyzing variants with respect 
to their group mates becomes important: The very different characteristics of peptides from 
various groups make it difficult to accurately compare the behavior of all peptides at the 
same time. 
 
Biophysical steady-state and kinetics studies. A variety of spectroscopic techniques were 
employed to probe the interaction between pHLIP variants and 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) phospholipid bilayers in liposomes; these techniques 
included steady-state fluorescence spectroscopy, circular dichroism (CD), oriented circular 
dichroism (OCD), and stopped-flow fluorescence measurements. Steady-state 
fluorescence and CD experiments were conducted in phosphate buffer titrated with 




published data (25, 29, 30). Steady- state and kinetics fluorescence experiments measuring 
the pH- dependent transition from state II to state III were carried out in phosphate buffer 
containing the physiological concentrations of free calcium (1.25 mM) and magnesium 
(0.65 mM) ions found in blood, since we expected that some of the constructs might bind 
these ions. 
We established that, in solution, PEG-2WT and PEG-4WT most probably exist in compact 
coil conformations, where tryptophan and other aromatic residues can form stacking 
structures. The resulting exciton formation was seen as a minimum around 230 nm in the 
CD spectra of these pHLIP bundles (Fig. 1 E and F). At pH 8, changes in the tryptophan 
fluorescence show that both constructs interact with the lipid bilayer, and it appears that 
PEG-4WT exhibits stronger binding than PEG-2WT in state II. With a reduction of pH, 
both pHLIP bundles inserted into the bilayer to form helices, and the TM orientations of 
these helices were confirmed by OCD measurements (Fig. 1 G and H). It is important to 
note that, in state III, the membrane-inserted state, the exciton signal generated by π−π 
stacking is no longer present, suggesting that the insertion of each pHLIP renders it in - 
dependent of the other(s). The pK of the transition from state II to state III was shifted to 
pH 6.6, and, as might be expected, the cooperativity of the transition was increased for 
PEG-4WT compared with PEG-2WT (Fig. 1 I and J). 
We compared the groups consisting of WT, Var3, and ATRAM pHLIP variants to the 
newly designed Var3/Gla and Var3/GLL pHLIP variants. The HPLC retention times of the 
peptides indicate increasing hydrophobicity within the groups in the following order, from 
less to more hydrophobic: WT, WT/Gla, WT/Gla/Aad and Var3, Var/Gla, Var3/GLL, and 
ATRAM, with ATRAM being the most hydrophobic (Table S2). Both new pHLIP variants, 
Var3/Gla and Var3/GLL, demonstrated a pH-dependent interaction with the membrane 




8, which reflects a higher affinity of the peptide for the lipid bilayer both at physiological 
and high pH due to the increased hydrophobicity of the peptide. 
As seen for previous pHLIP designs, a blue shift (or decrease in Stokes  shift) resulting 
from the environmental changes from state I to state II and state III was observed for all 
peptides (Table S3), indicating partitioning of the peptides into the lipid bilayer. However, 
we cannot directly compare the positions of fluorescence spectra maxima for peptides 
belonging to the different groups, since the locations of the tryptophan residues within the 
peptides varies greatly. With this fact in mind, we can conclude that the peptides had very 
different conformations in state II at pH 8, and that the highest membrane affinity was 
exhibited by the PEG-pHLIPs and by the WT/Gla/Aad, Var3/ GLL, and ATRAM peptides. 
The PEG-pHLIPs have multiple binding sites due to the linking of multiple WT peptides 
within a single construct, which is expected to enhance binding affinity. The WT/Gla/Aad, 
Var3/GLL, and ATRAM have the most hydrophobic sequences, and thus exhibit strong 
binding/insertion. We also found that some peptides were especially sensitive to the 
presence of calcium and magnesium ions, namely WT, variants containing the Gla residue 
(WT/Gla, WT/Gla/Aad, and Var3/ Gla), and ATRAM. This sensitivity was most obviously 
seen as a decreased Stokes shift (usually 2 nm to 3 nm) in state I and/or state II, and might 
reflect slight increases in the hydrophobicity of the peptides caused by the coordination of 
divalent cations resulting from the presence of closely spaced protonatable residues, such 
as those found in the C-terminal region of WT and, to some degree, in ATRAM, or to the 
presence of the Gla residue, with its two protonatable carboxyl groups, in the WT/Gla, WT/ 
Gla/Aad, and Var3/Gla peptides. It is known that a Gla residue can form a complex with a 
calcium ion (31–33). The decrease in Stokes shift in state II is likely due to the location of 




hydrophobic pHLIPs: WT/Gla/Aad, Var3/GLL, and ATRAM) and/or a shift in peptide 
population from the solvated to the membrane-adsorbed state. 
In contrast to tryptophan fluorescence changes, which are de- pendent on the location of 
tryptophan residues within the peptide sequence, the appearance of helicity is a more 
general parameter which can be compared among all peptides. In Fig. 2A (and Table S3), 
we give the ratio of ellipticity at 205 nm to 222 nm, an indicator of the degree of helicity 
(lower ratios indicate higher helicity), obtained for different peptides in different states. In 
state I, the lowest ratios were observed for pHLIP bundles, which correlate with the 
appearance of the exciton signal at 230 nm. In state II, the most structured peptides (ratios 
< 1.5) were PEG- 4WT, WT/Gla/Aad, Var3/GLL, ATRAM, and PEG-2WT, which 
exhibited a higher affinity to the membrane and an increase in the  peptide-inserted 
population at pH 8. At low pH, all peptides exhibited similar helical content, as expected 
from the formation of TM helices. 
The transitions from state II to state III seen in steady-state and kinetics modes exhibited 
pK values in the range of pH 5.7 to 6.6 in the presence of physiological concentrations of 
calcium and magnesium ions, with the highest cooperativity observed for PEG-4WT, and 
transition times varying from 0.1 s to 37.5 s (Table 2). There are subtleties that affect the 
comparison and interpretation of the data such as: (i) The peptides are in different starting 
conditions in state II at pH 8 due to greatly dif fering overall peptide hydrophobicity; (ii) 
difference in peptides pK values, which reflect equilibrium between peptides’ mem- brane-
adsorbed and membrane-inserted populations; (iii) characteristic times, which report the 
movement of tryptophan residues into environments inside the membrane; however, since 
the tryptophan residues are located in different regions of each pHLIP, their movement into 
the membrane, as measured via changes in fluorescence parameters, should be expected to 




what unstable parameter in the fitting of experimental pH- dependence data using the 
Henderson−Hasselbalch equation, especially if slopes are introduced at the initiation and 
completion of the transition (34). Lower values of cooperativity (n < 1) were observed for 
the peptides with tryptophan residues located at (Var3 group) or close (ATRAM) to the C 
terminus, which must be translocated across the cell membrane. ATRAM and Var3/GLL, 
which are the most hydrophobic pHLIPs and are therefore likely to be located more deeply 
than others in the membrane at pH 8, demonstrated the fastest times of insertion. As we 
showed previously, the removal of protonatable residues from the inserting C terminus 
increases the rate of the transition from state II to state III (24, 25). Thus, the group of 
Var3-like peptides exhibited fast insertion times (t < 1 s), a characteristic most attributable 
to the presence of less protonatable residues in the Var3-like peptides as well as a decrease 
in the number of these residues located at the C-terminal ends of the peptides. In the group 
of WT peptides, the time of insertion decreased as the hydrophobicity of the peptide 
increased, with insertion times listed in the following order (from longest to shortest time 
of insertion):  WT, WT/Gla, WT/Gla/Aad, PEG-2WT, and PEG-4WT. 
Intracellular delivery of polar cargo. We asked whether the pHLIP bundles could cause 
any acute cytotoxicity by themselves. HeLa cells were treated with either PEG-2WT or 
PEG-4WT at physiological pH (pH 7.4) and low pH (pH 6.0) for 2 h. We did not observe 
any cytotoxic effect at either pH, even when treating with concentrations up to 10 μM 
(construct concentration is presented as concentration of WT pHLIP). 
A proliferation assay was employed to evaluate the ability of pHLIPs to deliver the 
amanitin toxin, a relatively cell-impermeable, polar cargo molecule (35, 36). For amanitin 
to induce cytotoxicity, it must be translocated across the cell membrane, be released from 
the peptide carrier, and reach its target in the nucleus (RNA polymerase II). Amanitin was 




translocation capabilities of the pHLIP-amanitin conjugates were measured as the 
inhibition of proliferation of HeLa cells treated with increasing concentrations (up to 2 μM) 
of pHLIP-amanitin at either physio- logical pH (pH 7.4) or low pH (pH 6.0) for 2 h, 
followed by removal of the constructs, transfer of cells to normal cell culture media, and 
assessment of cell death at 48 h. 
Each of the conjugates demonstrated pH-dependent cytotoxicity (Fig. S2). The calculated 
EC20, EC50, and EC80 at physio- logical and low pH are shown in Table 2. At low pH, 
the most potent constructs were the pHLIP bundles, which exhibited the highest 
cooperativity of transition from membrane-adsorbed to membrane-inserted states. The 
least toxic at normal pH among all constructs was Var3. Fig. 2B lists the therapeutic 
indexes (TIs), defined as the ratio of EC50 at pH 7.4 to EC50 at pH 6.0 for each case. A TI 
of about 9 was obtained for WT/Gla and Var3, and the TI was around 5.5 for PEG-2WT, 
Var3/Gla, and ATRAM. It is desirable to have high potency, which is defined as a 
difference between cell viability at low and physiological pHs at different concentrations 
of the construct (Fig. 3). All constructs had high potency (60 to 70%) at particular 
concentrations; however, just a few constructs, namely Var3, Var3/Gla, and WT/ Gla, had 
a high, stable potency over a wide range of concentrations. The pHLIP bundles displayed 
the highest potency at the lowest concentrations (0.1 μM to 0.2 μM). The potency of 
ATRAM peaked at concentrations around 0.5 μM and declined sharply at higher 
concentrations; this decline is most likely associated with the increased hydrophobicity of 
ATRAM, which results in a high affinity for the cell membrane at normal and high pH and 
promotes the shift in equilibrium toward the membrane-inserted form that is associated 





Tumor targeting. To evaluate the tumor targeting and bio- distribution characteristics of 
the pHLIP variants, we conjugated the fluorescent dye Alexa Fluor 546 (AF546) to the 
noninserting, N termini of seven of the peptides. Our previous data indicate excellent tumor 
targeting by AF546-pHLIPs (9, 27). In the case of pHLIP bundles, AF546 was conjugated 
to the inserting, C termini of the PEG-2WT and PEG-4WT pHLIPs, as the N termini were 
occupied by PEG polymers. A well-established mouse model, using implanted cells of 
acidic 4T1 murine breast tumors, was used in the study; this model is targeted well by 
pHLIPs (9, 27). Following the development of breast tumors in the mouse flank, each 
fluorescent construct was introduced by a single tail vein injection. Animals were killed 4 
h after the injection of the fluorescent conjugates, and the tumor and major organs (kidney, 
liver, lungs, spleen, and muscle) were collected and imaged. We selected the 4 -h 
postinjection time point based on previous pharmacokinetics data which show that the 
highest tumor targeting with pHLIPs is observed 4 h after the injection of construct (9, 27). 
The mean values of the surface fluorescence intensity of tumors, muscle, and organs are 
given in Table S4. The normalized tumor fluorescence intensity (normalized by tumor 
uptake of AF546-WT) for all constructs is shown in Fig. 4A. The highest tumor targeting 
was observed for the Var3 construct, as well as for Var3/Gla and ATRAM. The tumor 
uptakes of the WT and Var3/GLL constructs were significantly reduced, by 1.6 - and 2.6-
fold, respectively, compared with the uptake of Var3. The uptakes of WT/Gla, 
WT/Gla/Aad, and the pHLIP bundles were reduced even further compared with the uptake 
of the WT construct. It is possible that the decreased tumor targeting observed in the PEG-
pHLIP bundles might be attributed to the fact that the AF546 dye was conjugated to the C 
terminus, which is translocated into the cytosol. At the same time, the tumor-to-muscle 
ratio of the WT-like group was in the range of 5.4 to 7.5. The highest tumor-to-muscle 




ratio was observed in Var3/GLL (T/ M = 4.0) (Fig. 4B and Table S5). Among all 
constructs, only Var3/GLL demonstrated a tumor-to-kidney ratio less than 1 (Fig. 4C and 
Table S5). The highest tumor-to-liver ratio was found in Var3 and Var3/Gla (Fig. 4D and 
Table S5). 
Because PEG-2WT-AF546 and PEG-4WT-AF546 are several times larger than the other 
pHLIP variants, we expected that they might have slower pharmacokinetics. Therefore, we 
also performed imaging at the 24-h postinjection time point for the two PEG-pHLIP 
conjugates; however, we did not observe any significant signal increase in tumors at 24 h 




To advance cancer therapy using a range of agents with different properties, we have 
developed new versions of pHLIP variants and pHLIP bundles, and compared their 
performance to the performance of recently introduced variants with nonstandard amino 
acids (Gla and Aad) and the hydrophobic GLL motif. Our goal was to correlate the 
biophysical properties of the membrane interactions of different pHLIPs, including 
physiological concentrations of free calcium and magnesium ions, to the ability of these 
pHLIPs to move polar cargo across the cell membrane and to target acidic tumors. 
The thermodynamic parameters of pK and cooperativity of pH-dependent transition from 
State II at pH 8 to State III at pH < 5 can be taken as predictors of the performance of a 
pHLIP for drug delivery and tumor targeting (17, 28, 29). While pK is a rather stable fitting 
parameter, the cooperativity parameter (Hill coefficient) might vary over a wide range 
resulting from different fittings which are within the level of accuracy of the experimental 




loses validity. In general, highly cooperative transitions are hard to measure in biological 
systems with noise, especially when examining relatively short peptides like the class of 
pHLIP peptides (28). Only if the biological system is approximated to be infinite can a 
phase transition occur (37). Moreover, transition parameters for different peptides can only 
be truly compared when both peptides have precisely the same starting and ending states; 
although this condition is met for the membrane-inserted state (state III) of the peptides, 
which appears very similar among pHLIP variants, the condition that the initial state (state 
II) of the peptides be identical is not met. As hydrophobicity varies widely among peptides 
of the pHLIP family due to the difference in numbers of protonatable, polar, and 
hydrophobic residues and their location within the peptide sequences, the characteristics of 
the peptide population in the initial state of the transition also varies as these peptides 
position themselves at different interaction levels with the hydrophobic/hydrophilic 
boundary region of a bilayer. 
The population percentages of inserted peptide presented in Table S6 were calculated from 
the pH-dependent transitions of pHLIP variants. The numbers represent the percentage of 
membrane-inserted peptides at varying pH assuming that, at the beginning of the transition 
(state II) (i.e., at physiological pH and higher), the population of inserted peptides is close 
to zero. In reality, close consideration of the interaction between a pHLIP variant and the 
membrane at pH 8, in conditions more alkaline than physiological conditions where the 
inserted peptide population should be even less than at physiological conditions, indicates 
that the most hydrophobic sequences, such as ATRAM and Var3/GLL, and bundled 
pHLIPs with multiple binding sites within a single construct, exhibit a significant inserted 
peptide population, as shown by the loss of pH-dependent differences in the translocation 
of the polar, cell-impermeable cargo amanitin with an increase in construct concentration 




using the pore-forming peptide melittin, helix formation, membrane binding, and insertion 
properties are very sensitive to primary structure changes involving glycine and leucine 
residues (38). Ultimately, due to patient variability, it is highly desirable that potential 
therapeutic pHLIP constructs are able to discriminate between healthy and tumor tissue 
over a wide concentration range, meaning that a constant potency is necessary to avoid 
targeting normal tissue and the resulting significant side effects, suggesting that the 
properties of these variants may not be well suited for clinical development using agents 
that require tight targeting. 
In addition to the steady-state experiments, it is important to probe tumor targeting and to 
examine the biodistribution of the constructs when injected into the high-flow-rate blood 
stream, since targeted delivery is always opposed by clearance from the blood. The best 
tumor targeting was shown by faster-inserting pHLIP constructs. Thus, in the design of 
new pHLIP variants, the biophysical kinetics parameters need to be considered in addition 
to the more traditionally prioritized steady-state properties. These kinetics parameters 
might be especially critical for the delivery and translocation of a cargo across a membrane, 
since we have shown that charges and the presence of cargo at the inserting end of a pHLIP 
can slow the process of insertion (24). Different cargoes linked to a pHLIP alter 
biodistribution and tumor targeting (27). Less polar pHLIP variants conjugated with 
hydrophobic cargoes might have a higher tendency toward targeting normal tissue and 
hepatic clearance. On the other hand, the size of links in pHLIP bundles could be used to 
tune biodistribution and redirect clearance from renal to hepatic. 
Among the pHLIP variants we investigated, Var3 demonstrated excellent performance in 
vitro (the most stable potency over a wide range of concentrations) and high tumor 
targeting. Variants containing the Gla residue, especially the WT/Gla construct, showed an 




(28), and showed an improved TI. However, the tumor targeting of WT/Gla was lower 
compared with the tumor targeting of WT. 
The γ-carboxyglutamic acid is not naturally encoded in the human genome, but is 
introduced into proteins through the posttranslational carboxylation modification of 
glutamic acid, resulting in an amino acid with two carboxyl groups. Several proteins are 
known to have Gla-rich domains, including many coagulation factors, which coordinate 
calcium ions, inducing conformational changes in the proteins that enhance the 
hydrophobicity and affinity of the proteins to the cell membrane bilayer (39). Calcium 
complex formation by a pHLIP increases the hydrophobicity of the peptide and alters the 
interaction be- tween peptide and membrane; this fact, along with the fact that the cost of 
synthesizing a Gla-containing peptide is very high (Gla is one of the most expensive amino 
acids) might somewhat reduce enthusiasm in using the Gla residue, but, if there were 
sufficient advantages in a specific case, the cost might be justified. While considering 
peptide synthesis, it is worthwhile to note that very hydrophobic pHLIP sequences (like 
ATRAM), especially when coupled with even moderately hydrophobic cargoes, might be 
challenging to produce in the large quantities needed for clinical translation.  
There is no single recipe for the best pHLIP: The peptide will need to be tailored to each 
specific medical application. For example, kidney clearance might be preferred to liver 
clearance for PET-pHLIP imaging constructs (13). High tumor-to-normal tissue 
fluorescence intensity ratios will be the key in fluorescence-guided surgical applications 
(11). Delivery of highly toxic molecules, such as amanitin, would require minimal off-
targeting; thus high potency and TI will be critical. However, for the delivery of polar 
peptide nucleic acids or other highly specific inhibitors of particular pathways in cancer 
cells, neither of which are associated with toxicity in normal cells, the requirement to 




efficiency of delivery, the goal being to translocate as much cargo as possible (18, 40). The 
pHLIP bundles might yield excellent results in these types of applications, supported by 
the observation that PEG-4WT is the most efficient at delivering the polar molecule 
amanitin to the intracellular space. We believe that bundling multiple Var3 pHLIPs, in the 
same fashion that we linked two or four WT pHLIPs, might be more advantageous. Var3 
demonstrates membrane insertion rates orders of magnitude faster than the insertion rates 
of WT; with the knowledge that faster insertion rates observed in biophysical experiments 
correlate to better tumor targeting in vivo, it stands to reason that potential PEG-Var3 
constructs might demonstrate better tumor targeting still. 
In drug delivery applications, pHLIP peptides are best designed for the delivery of polar, 
cell-impermeable molecules (14, 35, 41, 42). The intracellular delivery of a polar cargo 
could be further tuned by altering the link connecting the cargo to pHLIP and/or by 
attaching modulator molecules to the inserting end of the peptide (14, 15, 18, 35). 
Additionally, pHLIP could be used for the targeted delivery of cell-permeable, drug-like 
molecules since it can significantly increase the time of retention in blood, positively alter 
the biodistribution of drugs that typically rely on passive diffusion, and enhance tumor 
targeting, all of which would lead to an increase in TI (16). More polar pHLIP variants are 
expected to be better suited to applications involving the intracellular delivery of cell-
permeable cargoes. 
We have now established a set of properties for a number of pHLIPs, which can be selected 
as starting points for clinical development in different circumstances. This body of work, 
with the prior studies, opens pathways for targeted delivery using a range of imaging and 
therapeutic agents in the fight against cancer. 




pHLIP characterization and pHLIP bundle synthesis. All peptides were purchased 
from CS Bio Co. Peptides were characterized by reversed phase high-performance liquid 
chromatography (RP-HPLC) using Zorbax SB-C18 and Zorbax SB-C8, 4.6 × 250 mm, 5 
μm columns (Agilent Technology). For biophysical measurements, PEG-2WT and PEG-
4WT were made by conjugating either 2 kDa bifunctional maleimide-PEG-maleimide or 2 
kDa 4-arm PEG-maleimide (Creative PEGWorks) to Cys-WT via an N-terminal cysteine 
residue. Purification of the PEG-pHLIP constructs was conducted using RP-HPLC. Peptide 
concentration was calculated by absorbance at 280 nm, where, for WT, WT/Gla, and 
WT/Gla/Aad, ε280 = 13,940 M-1 cm-1; for Var3, Var3/Gla, and Var3/GLL, ε280 = 12,660 M-
1 cm-1; and for ATRAM, ε280 = 5,690 M-1 cm-1. PEG construct concentration was presented 
in terms of peptide concentration, not molecular concentration. 
 
Liposome preparation. Small unilamellar vesicles were used as model membranes and 
were prepared by extrusion. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC; 
Avanti Polar Lipids) was dissolved in chloroform at a concentration of 12.5 mg/mL, then 
desolvated by rotary evaporation for two hours under vacuum. The resulting POPC film 
was rehydrated in 10 mM phosphate buffer at pH 8, either with additional calcium and 
magnesium ions (1.25 mM calcium and 0.65 mM magnesium), or without additional ions, 
vortexed, and extruded fifteen times through a membrane with a pore size of 50 nm.  
 
Steady-state fluorescence measurements. Steady-state fluorescence spectra were 
measured using a PC1 spectrofluorometer (ISS) with temperature control set to 25.0 °C. 
The tryptophan fluorescence was excited using an excitation wavelength of 295 nm. 
Excitation and emission slits were set to 8 nm, and excitation and emission polarizers were 




experiments to allow for State II equilibration. A buffer-only sample was used as a baseline 
for State I, and a buffer-with-POPC-only sample was used as a baseline for States II and 
III. 
 
pH dependence measurements. Measurements of pH dependence were taken with the 
PC1 spectrofluorometer by using the shift in the position of maximum of peptide 
fluorescence as an indication of changes of the peptide environment at varying pH. All pH 
dependence measurements were conducted using blood physiological concentrations of 
free calcium and magnesium ions (1.25 and 0.65 mM, respectively). After the addition of 
hydrochloric acid, the pH of solutions containing 5 µM peptide and 1 mM POPC were 
measured using an Orion PerHecT ROSS Combination pH Micro Electrode and an Orion 
Dual Star pH and ISE Benchtop Meter (Thermo Fisher Scientific) before and after 
spectrum measurement to ensure equilibration. The tryptophan fluorescence spectrum at 
each pH was recorded, and the spectra were analyzed using the Protein Fluorescence and 
Structural Toolkit (PFAST) (42) to determine the positions of spectral maxima (𝜆max). The 
position of 𝜆max was plotted as a function of pH and normalized, such that 𝜆max
initial − 
position of spectral maximum in State II was set to 1 and 𝜆max
final − position of spectral 
maximum in State III, was set to 0. The normalized pH-dependence was fit with the 
Henderson-Hasselbach equation (using OriginLab software) to determine the cooperativity 
(𝑛) and transition mid-point (p𝐾) of transition of the peptide population from State II to 
State III: 
 
 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑝𝐻 𝑑𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑐𝑒 =
1
1+10𝑛(pH−p𝐾)





Steady-state circular dichroism and oriented CD measurements. Steady-state CD was 
measured using an MOS-450 spectrometer (Bio-Logic Science Instruments) in the range 
of 190 to 260 nm with a step size of 1 nm, and with temperature control set to 25.0 °C. 
Samples were prepared 24 hours prior to experiments to allow for State II equilibration. A 
buffer-only sample was used as baseline for State I, and a buffer-with-POPC-only sample 
was used as baseline for States II and III. 
 OCD was measured using supported planar POPC bilayers prepared using a  
Langmuir-Blodgett system (KSV Nima). Fourteen quartz slides with 0.2 mm spacers were 
used; after sonicating the slides in 5% cuvette cleaner (Contrad 70; Decon Labs) in 
deionized water (≥18.2 MΩ cm at 25 °C; Milli-Q Type 1 Ultrapure Water System, EMD 
Millipore) for fifteen minutes and rinsing with deionized water, the slides were immersed 
and sonicated for ten minutes in 2-propanol, sonicated again for ten minutes in acetone, 
sonicated a final time in 2-propanol for ten minutes, and rinsed thoroughly with deionized 
water. Lastly, the slides were immersed in a 3:1 solution of sulfuric acid to hydrogen 
peroxide for five minutes and rinsed three times in deionized water. The slides were stored 
in deionized water until they were used. POPC bilayers were deposited on the fourteen 
slides using a Langmuir-Blodgett minitrough: a 2.5 mg/mL solution of POPC in 
chloroform was spread on the subphase (deionized water) and the chloroform was allowed 
to evaporate for fifteen minutes, after which the POPC monolayer was compressed to 32 
mN/m. A lipid monolayer was deposited on the slides by retrieving them from the 
subphase, after which a solution of 10 µM peptide and 500 µM of 50 nm POPC liposomes 
at pH 4 was added to the slides, resulting in the creation of the supported bilayer by fusion 
between the monolayer on the slides and the peptide-laden lipid vesicles. After incubation 
for six hours at 100% humidity, the slides were rinsed with buffer solution to remove excess 




Measurements were taken at three points during the experiment: immediately after the 
addition of the peptide/lipid solution (0 h), after the slides were rinsed to remove excess 
liposomes following the six-hour incubation time (6 h), and after an additional twelve-hour 
incubation time and rinse with buffer (18 h); these measurements were recorded on the 
MOS-450 spectrometer with sampling times of two seconds at each wavelength. Control 
measurements were conducted using a peptide solution between slides without supported 
bilayers and in the presence of POPC liposomes. 
 
Kinetics measurements. Stopped-flow fluorescence measurements were made using an 
SFM-300 mixing system (Bio-Logic Science Instruments) in conjunction with the MOS-
450 spectrometer. All solutions were degassed for fifteen minutes prior to loading into the 
stopped-flow system. pHLIP variants were incubated with POPC for 24 hours prior to the 
experiment to reach State II equilibrium, and insertion was induced by mixing equal 
volumes of pHLIP/POPC solutions with hydrochloric acid diluted to ensure a pH drop from 
pH 8 to pH 4. Kinetics data were fit by one-, two-, three-, or four-state exponential models 
in OriginLab. 
 
Amanitin pHLIP conjugates. α-amanitin (Sigma-Aldrich) was conjugated to 
succinimidyl 3-(2-piridyldithio)propionate) (SPDP; Thermo Fisher Scientific), followed 
by purification and conjugation of the SPDP-amanitin to the C-terminal cysteine residues 
of pHLIP peptides. For synthesis of PEG-2WT-amanitin and PEG-4WT-amanitin, Lys-
WT-Cys with N-terminal lysine and C-terminal cysteine residues was used, and the Lys-
WT-SPDP-amanitin was conjugated to dibenzocyclooctyne-sulfo-N-hydroxysuccinimidyl 
ester (DBCO-NHS ester; Sigma-Aldrich), resulting in DBCO-WT-SPDP-amanitin. 




SPDP-amanitin, resulting in PEG-DBCO-WT-SPDP-amanitin, with a cleavable disulfide 
bond present in SPDP, between the peptide and amanitin cargo. Construct concentration 
was calculated by absorbance at 310 nm, where, for α-amanitin, ε310 = 13,000 M-1 cm-1. 
Construct concentration was presented in terms of peptide/amanitin concentration. 
Purification was conducted using RP-HPLC. Zorbax SB-C18 columns (9.4 × 250 mm, 5 
µm; Agilent Technologies) were used for all peptide-amanitin conjugates other than 
ATRAM-amanitin, PEG-2WT-amanitin, and PEG-4WT-amanitin, for which Zorbax SB-
C8 columns (9.4 × 250 mm, 5 µm; Agilent Technologies) were used.  
 
Cell proliferation assay. Human cervix adenocarcinoma cells (HeLa; American Type 
Culture Collection) were authenticated, stored according to the instructions of the supplier, 
and used within three months of frozen aliquot resuscitation. Cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) at pH 7.4 with 4.5 g/L D-
glucose, supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma-
Aldrich) and 10 µg/mL ciprofloxacin (Sigma-Aldrich), in a humidified atmosphere of 5% 
CO2 and 95% air at 37 °C. The pH 6.0 medium was prepared by mixing 13.3 g of dry 
DMEM in 1 L of deionized water. HeLa cells were loaded in the wells of 96-well plates 
(5,000 cells/well) and incubated overnight. The standard growth medium was replaced with 
medium without FBS, at pH 6.0 or 7.4, containing increasing amounts of pHLIP-amanitin 
conjugates (from 0 to 2.0 µM). Treatment with amanitin alone for two hours and at 
concentrations up to 2 µM does not induce cell death (35). After two-hour incubation with 
the pHLIP-amanitin conjugates, the constructs were removed and replaced with standard 
growth medium. Cell viability was assessed after 48 hours using the CellTiter 96 AQueous 
One Solution Cell Proliferation Assay (Promega); the colorimetric reagent was added to 




prepared in triplicate, and each experiment was repeated between 3 and 6 times. All 
obtained cell proliferation data were normalized by corresponding controls (non -treated 
cells). There was no difference in the viability of cells incubated with media, without 
construct, at pH 7.4 and pH 6.0; therefore, the role of pH was excluded from the 
consideration. Normalized cell viability data obtained in different experiments were 
averaged and presented in terms of the logarithm of dose of pHLIP-amanitin constructs. 
The dose-response function was used for fitting the obtained data (Figure S2) (OriginLab): 
 
𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 𝐴𝑏 +
𝐴𝑡−𝐴𝑏
1+10𝑝(log 𝑥0−𝑥)
       (2) 
 
where 𝐴𝑏  and 𝐴𝑡  are the bottom and the top asymptotes, respectively. The top asymptote 
was set as constant (100%) while for the bottom asymptote we allowed small variations in 
the range of 0 to 10%. 𝑝 is the slope (cooperativity parameter) and log 𝑥0 is the center of 
the transition (i.e., the concentration for half response) which is used to calculate the EC20, 
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𝐸𝐶50 = 10
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p𝐻 6.0          (6) 
  
Additionally, the cytotoxicity of the PEG-2WT and PEG-4WT constructs without amanitin 
was tested: these experiments demonstrated no cytotoxicity at physiological or low pH at 
treatment concentrations up to 10 µM. 
 
Fluorescent pHLIP conjugates. Alexa Fluor 546 (AF546) C5 maleimide (Thermo Fisher 
Scientific) was conjugated to the N-terminal cysteine residues of WT, Var3, Var3/Gla, and 
ATRAM. AF546 NHS Ester (Thermo Fisher Scientific) was conjugated to the N-terminal 
lysine residues of WT/Gla, WT/Gla/Aad, and Var3/GLL. For PEG-2WT and PEG-4WT, 
Cys-WT-Lys, with N-terminal cysteine and C-terminal lysine residues, was used, and was 
first conjugated to 2-arm maleimide-PEG-maleimide or 4-arm PEG-maleimide resulting in 
PEG-WT-Lys. Then, AF546 NHS Ester was conjugated to the C-terminal lysine residue, 
resulting in 2-arm and 4-arm PEG-pHLIP constructs with C-terminal AF546 fluorophores. 
Construct concentration was calculated by absorbance at 554 nm, where, for AF546, ε554 
= 93,000 M-1 cm-1. Construct concentration was presented in terms of AF546/peptide 
concentration, not molecular concentration. Purification was conducted using RP-HPLC 
for all peptides other than PEG-4WT-AF546, which was purified via Amicon Ultra 
MWCO 10 kDa centrifugal filter (Sigma-Aldrich). Zorbax SB-C18 columns (9.4 × 250 
mm, 5 µm; Agilent Technologies) were used for all AF546-peptide conjugates except 
AF546-ATRAM and PEG-2WT-AF546, for which Zorbax SB-C8 columns (9.4 × 250 mm, 
5 µm; Agilent Technologies) were used. 
 
Ex vivo imaging. All animal studies were conducted according to the animal protocol 




University of Rhode Island, in compliance with the principles and procedures outlined by 
the National Institutes of Health for the care and use of animals. Mouse mammary cells 
(4T1; American Type Culture Collection) were subcutaneously implanted in the right flank 
(8 × 105 cells/0.1 mL/flank) of adult female BALB/cAnNHsd mice (Envigo). When tumors 
reached approximately 5-6 mm in diameter, single tail vein injections of 100 µL, 40 µM 
fluorophore-pHLIP solutions in PBS were performed. Mice were euthanized 4 or 24 hours 
after injection, and necropsy was immediately performed. Tumors and major organs were 
cut in half and imaged using an FX Kodak in-vivo image station connected to an Andor 
CCD camera. Mean surface fluorescence intensity of tumor, tissue and organs was obtained 
via analysis of fluorescence images in ImageJ (NIH) (43). The corresponding 
autofluorescence signal was subtracted to obtain the net fluorescence intensities used in the 
study. Autofluorescence was calculated after imaging tumors, tissue, and organs collected 
from mice with no injection of fluorescent pHLIP constructs. 
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Table 2. The midpoint (pK), cooperativity (n), and time (t) parameters characterizing the 
pH-dependent transition of pHLIP variants in the presence of POPC liposomes are 
presented. EC20, EC50, and EC80 values were calculated for each pHLIP-amanitin construct 
at physiological and low pH by analyzing the pH- and concentration-dependent cell 
viability data (Figure S2). 
 
  
Peptide pK n t (s) 
EC20 (µM) EC50 (µM) EC80 (µM) 
pH 7.4 pH 6.0 pH 7.4 pH 6.0 pH 7.4 pH 6.0 
WT 6.5 1.8 36.8 1.95 1.22 1.37 0.56 0.96 0.26 
WT/Gla 6.2 1.5 37.5 6.20 0.93 2.73 0.30 1.20 0.10 
WT/Gla/Aad 6.6 1.4 34.8 3.01 0.66 1.39 0.37 0.64 0.21 
PEG-2WT 6.6 1.8 18.8 1.98 0.54 1.03 0.19 0.53 0.07 
PEG-4WT 6.6 2.2 13.1 0.473 0.19 0.33 0.11 0.23 0.06 
Var3 5.7 0.9 0.9 10.63 1.30 3.95 0.43 1.47 0.14 
Var3/Gla 6.3 0.7 0.7 5.12 1.34 2.76 0.50 1.48 0.19 
Var3/GLL 6.6 0.4 0.1 1.75 0.47 0.91 0.23 0.47 0.11 







Figure 1. Schematic organization of pHLIP bundles: (a) PEG-2WT with 2 kDa 2-arm PEG 
and two WT pHLIPs, and (b) PEG-4WT with 2 kDa 4-arm PEG and four WT pHLIPs. 
Transitions between the three states of PEG-2WT and PEG-4WT in phosphate buffer at 
pH 8 (State I), in the presence of POPC liposomes at pH 8 (State II), and in the presence 
of liposomes at pH 4 (State III) were monitored by changes of tryptophan fluorescence (c 
and d), circular dichroism (e and f), and oriented circular dichroism (OCD) (g and h) 
signals. Normalized pH-dependent steady-state transitions from State II to State III were 
examined by analyzing the shift in position of fluorescence spectrum maximum of PEG-




magnesium ions. The data were fitted using the Henderson-Hasselbalch equation; the 
fitting curves and 95% confidence interval are shown by red and blue lines, respectively. 
 
 
Figure 2. Ellipticity ratios of CD signals at 205 nm to 222 nm are shown for pHLIP variants 
in State I, II, and III (a). The values of ellipticity ratios are given in Table S3. The 
therapeutic index (TI) was calculated for different pHLIP-amanitin constructs as the ratio 








Figure 3. pH-dependent potency was defined as the difference between cancer cell 
viability when cells were incubated at pH 7.4 and pH 6.0 at varying concentrations of 
different pHLIP-amanitin constructs. The WT-like group is shown in (a); the Var3-like 








Figure 4. Normalized tumor fluorescence intensities of the AF546-pHLIP constructs are 
shown; the signals were normalized by the tumor intensity of AF546-WT (a). Tumor-to-
muscle (T/M) (b), tumor-to-kidney (T/K) (c), and tumor-to-liver (T/L) (d) fluorescence 
intensity ratios are shown. Statistically significant differences were determined by two-
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Novel approaches in synthesis of spherical and multispiked gold nanoparticles coated 
with polyethylene glycol (PEG) and pH Low Insertion Peptide (pHLIP®) were 
introduced. The presence of a tumor-targeting pHLIP® peptide in the nanoparticle 
coating enhances the stability of particles in solution and promotes a pH-dependent 
cellular uptake. The spherical particles were prepared with sodium citrate as a gold 
reducing agent to form particles of 7.0 ± 2.5 nm in mean metallic core diameter and 
∼43 nm in mean hydrodynamic diameter. The 
particles that were injected into tumors in mice (21 µg of gold) were homogeneously 
distributed within a tumor mass with no staining of the muscle tissue adjacent to the 
tumor. Up to 30% of the injected gold dose remained within the tumor one hour post-
injection. The multispiked gold nanoparticles with a mean metallic core diameter of 
146.0 ± 50.4 nm and a mean hydrodynamic size of ~161 nm were prepared using 
ascorbic acid as a reducing agent and disk-like bicelles as a template. Only the presence 
of a soft template, like bicelles, ensured the appearance of spiked nanoparticles with 
resonance in the near infrared region. The irradiation of spiked  gold nanoparticles by 
an 805 nm laser led to the time- and concentration-dependent increase of temperature. 
Both pHLIP® and PEG coated gold spherical and multispiked nanoparticles might find 
application in radiation and thermal therapies of tumors. 
 
Introduction 
Gold nanoparticles (ranging in size from 1 to 200 nm) might find various applications 
in medicine including the enhancement of x-ray radiation damage to tumor tissues [1–
4] and the induction of localized heating in photothermal therapy [5–7]. The latter is 




local environment due to the temporary existence and  decay  of localized surface 
plasmon polaritons. In addition of use of gold nanoparticles, also supermagnetic 
nanoparticles are developed for magnetic resonance imaging and hyperthermia to 
induce cancer cells death or promote drug release [8–13]. In all cases of nanoparticle  
use, not only should the particles be stable, but they should preferentially target 
diseased tissue, such as a cancerous tumor. 
Many contemporary therapeutic and imaging approaches to cancer treatment rely on 
tumor-targeting biomarkers such as antibody technologies or vitamin binding [14–18]. 
Although there are significant successes, the inter- and intra-heterogeneity of tumors, 
their complexity, and their ability to adapt to new conditions often create parts of a 
tumor that may not express enough of the biomarker to be targeted. This results in the 
regrowth of resistant tumors and poor therapeutic outcomes, where the average 
improvements in survival are measured in months. At the same time, there is an 
emerging body of evidence indicating that the acidity of the tumor tissue plays a key 
role in determining cancer cell invasiveness and resistance to therapies.  Tumors 
exhibit marked heterogeneity due to genetic alterations, which lead to the modification  
of biochemical pathways.  The modifications that result from metabolic alterations, 
lead to a surge in extracellular acidity. Tumor cells adapt to this acid-induced toxic 
environment by stimulating proteins that regulate intracellular homeostasis [19,20].  
Among pH-targeting agents, the family of pH Low Insertion Peptides (pHLIP®) find 
a broad range of applications in biomedical sciences. pHLIP® peptides insert across 
cellular membranes in a pH-dependent manner, with one terminus exposed to the 
extracellular space and the other terminus to the cytoplasm [21–24]. The molecular 
mechanism of a pHLIP® peptide's action is based on the protonation of Asp/Glu 




associated folding with the insertion of a transmembrane helix [25,26]. It was shown 
that pHLIP® peptides are excellent at targeting acidic tumors, which allows for the 
specific delivery of imaging and therapeutic agents to cancer cells within tumors 
[22,27–29]. The number and variety of pHLIP® based nanomedicines is growing. For 
example, the coating of lipid-based, polymeric, and metallic nanoparticles with 
pHLIP® peptides enhances the targeting of acidic tumors and the number of particles 
internalization within cancer cells [30–36]. 
We have shown specific tumor accumulation of gold nanoclusters of  
1.4 nm in diameter conjugated to the pHLIP® peptide [37], and an enhancement of 
radiation effect observed for cancer cells treated with pHLIP® gold nanoclusters [38]. 
As well, novel photo-induced pHLIP® coated hollow gold nanospheres containing 
chlorine 6 were introduced recently [33,34].  The   nanospheres   experience   
hyperthermia   within 5 min of laser exposure, which leads to the release of 
photosensitizers due to the reduction of electrostatic interaction. While the obtained 
results are very interesting and promising, there are aspects which require 
improvement and justify further work: i) the coating of gold nanoclusters conjugated 
with pHLIP® peptide should be improved to avoid particles aggregation; and ii) a 
greater amount of gold might be needed in tumors to observe a significant radiation 
enhancement effect. Therefore, here we introduce novel approaches for synthesis of 
pHLIP® and PEG coated spherical and spiked gold nanoparticles for the enhancement 
of radiation damage and near infrared (NIR) thermal therapy. 
 
Materials and Methods 
 





Gold III chloride, 5% solution, was purchased from Salt Lake Metals (Salt Lake City, 
UT). Sodium citrate tribasic, L-ascorbic acid, and urea dehydrate were purchased from 
Sigma-Aldrich Co. (St. Louis, MO). The wild type (WT) pHLIP® peptide: 
ACEQNPIYWARYADWLFTTPLLLLDLALLVDADET 
was synthesized and purified by C.S. Bio Co. (Menlo Park, CA), and the concentration 
of the peptide was determined by  absorbance  at  280 nm (ε=13,940 M−1 cm−1). The 
m-polyethylene glycol–SH (mPEG- SH), about 5 kDa in mass, was purchased from 
Creative PEGworks (Chapel Hill, NC). The lipids, 1,2-dihexanoyl-sn-glycero-3-
phosphocholine, D6PC; 1,2-diheptanoyl-sn-glycero-3-phosphocholine, D7PC/DHPC 
and 1,2-dimyristoyl-sn-glycero-3-phosphocholine, DMPC were purchased from 
Avanti Polar Lipids, Inc (Alabaster, AL). Tris-(2-carbox- yethyl) phosphine 
hydrochloride (TCEP) was purchased from Thermo Fisher Scientific (Waltham, MA). 
The procedures for synthesis of the spherical and multispiked pHLIP® and PEG coated 
gold nanoparticle are described in the Results section. 
 
2.2. Bicelle preparation 
 
Bicelles were prepared by thin-film method: a chloroform solution of DMPC and 
D7PC (DHPC) lipids were dried using a rotary evaporator producing an even thin film, 
followed by the additional overnight evaporation under a high vacuum to remove 
traces of organic solvents. The lipid layer was re-suspended in 10 mM phosphate buffer 
pH 6.5 and underwent ten freeze-thaw-vortex cycles using liquid nitrogen and a warm 





2.3. Purification of gold nanoparticles 
 
To remove large particles (in the case of spherical gold nanoparticles) and excess 
reducing agents, the final solution of particles under- went two forms of filtration. 
Large particles were removed using centrifugation (5 min at 10,000 relative centrifugal 
force, RCF). Excess reducing agents were removed by  size-exclusion  
chromatography  using  sephadex  G25  fast  spin  columns. 500 μL of particles were 
added to 5 mL of sephadex G25 gel filtration beads (Sigma-Aldrich Co.) (the beads 
were hydrated in the desired buffer) and centrifuged for 0.5 min increments at roughly 
36 RCF. The final nanoparticle solutions were passed through a 0.2 µm sterile 
Acrodisk® syringe filter with HT Tuffryn® membrane (Pall Life Sciences) f or 
sterilization when experiments on cultured cells and mice were carried out, as well as 
for stability studies and heating experiments. 
  
2.4. UV–visible absorption spectroscopy 
 
The absorbance of gold nanoparticles was recorded on a Genesys 10S UV–Vis 
Spectrophotometer to establish the wavelength range of resonance.  
 
2.5. Measurements of particles size 
 
The size of bicelles and gold nanoparticles in solution was measured by dynamic light 
scattering (DLS) using a Zetasizer Nano ZS (Malvern) instrument and a nanoparticle 
tracking system, Nanosight (NS300, Malvern), respectively. Transmission electron 




magnifications in the range of 10,000× to 150,000× was used to image gold 
nanoparticles to establish the shape, size, and homogeneity of the particles. Samples 
were prepared for TEM by drying 5 μL of the nanoparticle solution on a carbon type -
B, 300 mesh, copper grid (Ted Pella, Inc). Size histograms were averaged and fitted 
with a Gaussian function. 
 
2.6. ICP-MS analysis 
 
The investigated samples (cells, tumor tissue, or nanoparticles in solution) were 
dissolved in a concentrated solution of aqua regia (1:3 volume ratio of nitric acid and 
hydrochloric acid) and sonicated. The final solutions were diluted to 2% (wt/vol) nitric 
acid with distilled water and centrifuged to remove organic tissue. The gold content 
was quantified using inductively coupled plasma mass spectrometry (ICP- MS) 
(Thermo scientific X7 series and Thermo X-Series 2 quadrupole) by using calibration 




In a poly(methyl methacrylate) (PMMA) cuvette (with a 4.5 mm window width and 
12.5 mm depth), 300 μL of solution was illuminated by an 805 nm temperature 
controlled laser diode with 500 mW output (TCLDM9, Thorlabs). The solution 
temperature was measured every 
minute with an immobilized FLIR E6 thermal imager (FLIR Systems, Inc.) from above 
to avoid obstruction by the cuvette walls. A sample of phosphate-buffered saline 





2.8. Cancer cells 
 
JC murine mammary-gland adenocarcinoma cells were obtained from the American 
Type Culture Collection (ATCC). The cells were cultured in Roswell Park Memorial 
Institute (RPMI) medium supplemented with 10% fetal bovine serum (FBS) and 10 
μg/mL ciprofloxacin in a humidified atmosphere of 5% CO2 and 95% air at 37 °C. 
 
2.9. Cytotoxicity assay 
 
JC cancer cells were seated in a 96-well plate (3000–3500 cells per well in 100 μL 
RPMI medium) and incubated overnight. The next day, 100 μL of gold nanoparticles 
in PBS pH 7.4 supplemented with 10 mM D-glucose were added to the cells at two 
concentrations and incubated for 48 h. Final gold concentrations after addition to cells 
were 0.025 g/   L and 0.013 g/L (spherical particles) 0.010 g/L and 0.005 g/L (multi - 
spiked particles). Cell viability was assessed by a colorimetric reagent (CellTiter 96 
AQueous One Solution Assay, Promega), which was added to cells for one hour 
followed by the measurement of absorbance at 490 nm by an iMark Microplate 
Absorbance Reader (Bio-Rad Laboratories, Inc.). The absorbance readings were 
corrected for the absorbance of gold nanoparticles at 490 nm. All samples were 
prepared in triplicate.  
 





Various amounts of JC cancer cells  (from 100,000 to 1 million cells  in different 
experiments) were treated in suspension with purified spherical gold nanoparticles 
(0.83% citrate and 10% pHLIP-90% PEG) (typically the final concentration of gold 
with cells was 0.06 g/L)  for three hours at 37 °C in serum-free Leibovitz's L-15 
medium of pH 6.0 or pH 7.4 (final treatment volume was 500  μL). In another 
experiment, JC cells were pre-treated with gold nanoparticles in serum-free L-15 
medium at pH 7.4 for 20 min, and then media  (with  different  pHs)  were added to set 
a total volume of 500 μL and a final solution pH of 7.4 or 6.0–6.2. After treatment, 
samples were pelleted (5 min at 600 RCF) and washed with PBS, pH 7.4, three times. 
The amount of gold in each pellet was then quantified using ICP-MS. The amount of 
gold not taken up by cells was quantified in the supernatant by absorbance 
measurements. Control samples of gold nanoparticles without cells and cells without 
particles were investigated at both high and low pH as well. All samples were prepared 
in triplicate. 
 
2.11. Uptake and distribution of gold in tumors 
 
All animal studies were conducted according to the animal protocol AN07-01-015 
approved by the Institutional Animal Care and Use Committee at the University of 
Rhode Island, in compliance with the principles and procedures outlined in the 
National Institutes of Health Guide for the Care and Use of Animals.  Female Balb/C 
mice ranging in age from 4 to 6 weeks and weighing from 18 to 22 g were obtained 
from Envigo RMS, Inc; 16 mice were used   in the study.Tumors were established in 
the right flank by subcutaneous injection of  JC  cancer  cells (106 cells in 100 μL). 




(0.83%  citrate  and  10%   pHLIP-90% PEG) (5.5 µg of gold), or 0.42 g/L gold 
particles (21 µg of gold) in PBS, pH 7.4, supplemented with 10 mM D-glucose were 
injected intratumorally. An hour after injection, mice were euthanized and the tumors 
were immediately collected for histological and gold-quantification analysis. The 
amount of gold in each tumor was quantified using ICP-MS. A non-injected mouse 
with a similar-sized tumor was used as a negative control. The distribution of gold 
within the tumor was assessed by white light imaging of the tumor center.  
 
2.12. Histological staining and imaging of tumor sections 
 
Immediately after tumors were collected from the mice, they were frozen in tissue-tek 
OCT compound using liquid nitrogen and stored at −80 °C until sectioned at a 
thickness of 20 µm using a cryostat at −25 °C  (Vibratome  UltraPro5000,  GMI). 
Tumor sections were then fixed in a 4% paraformaldehyde solution (Sigma-Aldrich 
Co.), washed three times with deionized water, permeated with 0.3% Triton X-100 
(Sigma-Aldrich, Co.) in PBS, pH 7.4, for one hour, washed two times with  deionized 
water, and stained with HQ Silver™ silver enhancement solution (Nanoprobes, Inc) 
for 15 min followed by a final washing. The tumor sections were finally stained wi th  
3 μM 4′,6-diamidino-2-pheny-lindole (DAPI) (Molecular Probes, Thermo Fisher 
Scientific) for two and a half hours to mark cell nuclei. Adjacent tumor slides were 
fixed in 4% formaldehyde and stained with hematoxylin and eosin (H & E) (Thermo 
Fisher Scientific and Poly Scientific R & D Corp). The stained section  was covered 
with a drop of mounting medium (Permount®, Fisher Scientific) and then a cover slide 
was placed over the medium. The slides were examined under an inverted fluorescence 







We have synthesized and investigated pHLIP® and PEG coated gold nanoparticles. In 
our study we used WT pHLIP® peptide (4.1 kDa) with a single Cys residue at the N-
terminus and similar size of PEG polymer (about 5 kDa) with a single SH group. The 
pHLIP® and PEG were used in a mixture with reducing agents, tri-sodium citrate or 
ascorbic acid, to prepare spherical or spiked gold nanoparticles, respectively. The 
pHLIP® peptide was dissolved in a solution of 2.7 M urea and mixed (in equal parts) 
with degassed, deionized water containing a ten times molar-excess of TCEP, which 
prevents the formation of disulfide bonds. The PEG polymer was dissolved in 
degassed, deionized water containing a ten times molar-excess of TCEP. 
 
3.1. Synthesis and characterization of spherical pHLIP® and PEG coated gold 
nanoparticles 
 
To obtain pHLIP® and PEG coated spherical gold nanoparticles, the solution of gold 
III chloride was reduced using tri-sodium citrate mixed with pHLIP® peptide and PEG 
polymer. The solution containing gold III chloride, citrate, pHLIP®, and PEG was 
blown with argon and sealed for incubation at room temperature. Within 15–20 min a 
change in color of the solution was observed (Supplementary Fig. S1) and particles 
were left overnight at room temperature to ensure the complete reduction of the gold 
and coating of nanoparticles by pHLIP® and PEG. Interesting to note that presence of 




In the course of this study we varied the amount of citrate, pHLIP®, and PEG, and 
monitored the changes of nanoparticles size and absorbance of the nanoparticles 
solution for the appearance of a resonance peak at 525 nm (Fig. 1). The absence of 
pHLIP® and PEG leads to the aggregation of particles and precipitation within a 
couple of hours after their preparation (Supplementary Fig. S1 and Fig. 1a). The higher 
amount of citrate is expected to promote better stability of nanoparticles. However, our 
goal was an investigation of formation of gold nanoparticles in the presence of 
pHLIP® an PEG, which were found to enhance stability and solubility of 
nanoparticles. The best resonance was observed when gold nanoparticles were coated 
with both pHLIP® and PEG. The amount of sodium citrate was varied from 0.42% to 
2.8% wt/vol in the presence of 10% pHLIP® and 90% PEG in solution, where the 
concentration of citrate is reported as a final concentration in the nanoparticle solution 
(Fig. 1b). A low amount of citrate (0.42% wt/vol) in solution results in the shift and 
broadening of the resonance peak, as well as the appearance of large particles, which 
was confirmed by the nanoparticle tracking system (data not shown). At the same time, 
particle sizes did not change when the amount of citrate was varied from 0.83% wt/vol 
to 2.8% wt/vol. The best results (narrow resonance) were obtained for citrate 
concentrations in the range between 0.83% wt/vol and 1.7% wt/vol. There is a 
possibility that at high amount of citrate (2.8% wt/vol) in the presence of pHLIP® and 
PEG, the shape of particles might be altered, which leads to the broadening and shift 
of a resonance. 
The amount of pHLIP® peptide and PEG polymer was altered as well. An increased 
percentage of negatively charged pHLIP®, which slows down process of gold 
reduction, and decreased percentage of neutral PEG polymer leads to the broadening 




minimum amount of citrate (0.83% wt/vol), 10% pHLIP® and 90% PEG were chosen 
as an optimal, when resonance is narrow and there are enough pHLIP® peptides 
deposited to the surface of nanoparticles to preserve pH-dependent interaction of the 
coated nanoparticles with the lipid bilayer of a membrane. The final selected 
composition of reagents (0.83% citrate and 10% pHLIP-90% PEG) comprised the 
following molar parts: 0.5 parts of 10 mM gold III chloride; 0.075 parts of tri- sodium 
citrate (10% wt/vol); 0.1125 parts of 0.5 mM PEG with 5 mM T CEP; 0.0125 parts 0.5 
mM pHLIP® peptide with 5 mM TCEP and 1.35 M urea, and 0.3 parts of degassed 
deionized water. 
After synthesis, the solution of nanoparticles was purified to remove large particles 
and excess reducing agents. The large particles were removed by centrifugation.  The 
excess reducing agents were removed when the nanoparticles were transferred to PBS, 
pH 7.4 solution by size-exclusion chromatography. TEM imaging was employed to 
analyze nanoparticle size and shape distributions (Fig. 1e). The nanoparticles were 
homogeneous and round. The metallic core was about 7.0 ±2.5 nm in diameter 
(Supplementary Fig. S2a). The mean hydrodynamic size (diameter), determined by 
nanoparticle tracking system, was about 43 nm. 
Purified spherical gold nanoparticles coated with pHLIP® and PEG (0.83% citrate and 
10% pHLIP-90% PEG) were stable for at least 36 days at 4 °C in PBS, pH 7.4. The 
stability of gold nanoparticles in solution was assessed by visual appearance of 
precipitate, measurements of nanoparticle size and resonance peak by absorbance 
recording. The stability study was carried out on the particles at two different 
concentrations with gold amount of  0.10 g/L and 0.02 g/L. A high stability profile was 
obtained for both concentrations (Fig. 1d). At the same time, when particles were 




PEG, or without both PEG and pHLIP®, the stability was seriously compromised; 
particles settled over time forming large visible aggregates and the resonance peak was 
shifted and broadened (data not shown). Thus, the presence of pHLIP® peptide in gold 
nanoparticles coating is essential to maintain colloidal stability over time when using 
the methods described here. 
 
3.2. Templated synthesis and characterization of pHLIP® and PEG coated 
multispiked gold nanoparticles 
 
Another approach we explored in the preparation of  pHLIP® and PEG coated gold 
nanoparticles was based on use of bicelles as a soft template, to obtain irregularly 
shaped nanoparticles. Bicelles are disk-like micelles, which consist of long-chain and 
short-chain phospholipids or surfactants (Fig. 2a). The limitation in experiments using 
bicelles is typically the high critical micelle concentration (CMC) of lipids and 
detergents, which restricts the degree of bicelle dilution without the lipid phase 
transforming to vesicles. For example, the CMC of the widely used short-chain D6PC 
lipid is 14 mM. Thus, when the best characterized system of D6PC–DMPC bicelles 
are diluted below CMC, they are expected to be converted into a mixture of free D6PC 
lipids and DMPC lipid bilayer liposomes. It is known that D7PC lipids have a 10 times 
lower CMC (1.4 mM), and D7PC–DMPC mixtures retain bicelle properties at 
concentrations even as low as 0.1% wt/vol [39]. Therefore, we selected the DMPC-
D7PC lipid system and ensured that the addition of gold and reducing solutions does  
not lead to the dilution of lipids below 0.1% wt/vol. Assuming the DMPC and DHPC 




is expressed via q-values, which reflects different aspect ratios of disk-like bicelles 
[40,41]: 





πh (πR + h)
 
where R is the radius and h is the height of the bicelle (Fig. 2a). The height of the 
bicelles in our study was 4.2 nm and the radius varied depending upon the ratio of 
DMPC to DHPC lipids. The diameters of the bicelles of different asymmetry, d(q), 
calculated according to the above equation (without accounting for the DHPC capping) 
are the following: d(0.2)=4.2 nm; d(0.3)=6.0 nm; d(0.5)=8.6 nm; d(0.75)=12 nm; and 
d(1.0)=15 nm. To investigate the integrity of the D7PC-DMPC bicelle structures of 
various aspect ratios, we monitored their change in size at concentrations of 1.0%, 
0.5% and 0.1% wt/vol (Fig. 2b). Because we were only concerned with the change in 
size upon dilution, no attempts were made to account for asymmetric particle sizes in 
DLS measure- ments. A slight increase in size was observed at low concentrations 
(0.1% wt/vol) for bicelles with q-values less than 0.75. On the other hand, highly 
asymmetric bicelles with a q-value equal to 1 lose their structural integrity as a result 
of dilution. Therefore, all experiments were performed with bicelles of q -values of 
0.75 and lower. 
Templated synthesis of pHLIP® and PEG coated multispiked gold  nanoparticles was 
always initiated shortly after bicelle preparation. We ensured that the addition of gold 
solution and reducing agents does not lead to the dilution of the bicelle solution to lipid 
concentrations less than 0.1% wt/vol. The following steps were performed in synthesis 
of multispiked gold nanoparticles: i) a solution of gold III chloride was added to the 
solution of bicelles and mixed; ii) next, the reducing agent, ascorbic acid,  was added 
very carefully; and iii) upon color change (~30s) the solution containing pHLIP® and 




absorbance (Fig. 3a) along with TEM imaging (Fig. 3b) was indicative of the formation 
of multispiked gold nanoparticles. In the absence of bicelles, the resonance shifted to 
525 nm (Fig. 3a), reflecting the formation of solid spherical gold nanoparticles, which 
was also confirmed by TEM. Interestingly, the use of citrate as a reducer instead of 
ascorbic acid shifts the equilibrium towards the formation of solid spherical gold 
particles rather than the templated synthesis of spiked gold nanoparticles (data not 
shown). The change of bicelle asymmetry (increase of q-values from 0.3 to 0.75) does 
not affect appearance of NIR resonance (Fig. 3a). Variation in the amount of gold in 
the range   from 1:0.5 to 1:3 lipid:gold ratios did not significantly affect the appearance 
of the resonance peak. The normalized absorbance of nanoparticles does not change 
upon dilution or the addition of a detergent that disrupts lipid structures, Triton X-100, 
indicating nanoparticle stability and integrity after synthesis (data not shown).  The 
presence of pHLIP® and PEG resulted in the formation of particles that were more 
stable in aqueous solution compared to the particles without coating, which were 
precipitated shortly after their prepara- tion. The final composition of the reagents was 
the following molar parts: 0.05 part of 15 mM of lipids arranged into bicelles (> 0.1% 
wt/ vol), 0.15 parts of 5 mM gold III chloride; 0.0225 parts of 250 mM ascorbic acid; 
0.414 parts of 0.5 mM PEG with 5 mM TCEP; 0.046 parts 0.5 mM pHLIP® peptide 
with 5 mM TCEP and 1.35 M urea; and 0.3175 parts of degassed, deionized water.  
TEM imaging performed on filtered pHLIP® and PEG coated gold nanoparticles 
demonstrated the presence of irregular, multispiked gold nanoparticles (Fig. 3b). The 
structures were the same for bicelles with different q-values. Conversely, multispiked 
structures were not observed in absence of bicelles. The mean core size (diameter) of 




Fig. S2b). The mean hydrodynamic diameter, deter- mined by nanoparticle tracking 
system, was about 161 nm. 
Different concentrations of pHLIP® and PEG coated multispiked gold nanoparticles 
were illuminated in solution by an 805 nm laser diode with 500 mW output. The laser 
radiant exposure was ~400 J/cm2. For particles at a concentration of 0.021 g/L gold, a 
temperature increase of 14 degree units (from 26 °C to 40 °C) was observed within 5 
min (Fig. 3c), which is ~18 J imparted to water or ~12% energy converted to heat. 
More concentrated particles showed greater temperature changes at all time points 
compared to less concentrated particles. 
 
3.3. Interaction of pHLIP® and PEG coated gold nanoparticles with cancer cells  
 
First, we have tested the cytotoxicity of pHLIP® and PEG coated spherical and 
multispiked gold nanoparticles. JC murine mammary-gland adenocarcinoma cells 
were treated with gold nanoparticles  (0.025 and 0.013 g/L of spherical; and 0.010 g/L 
and 0.005 g/L of multispiked) for 48 h. The obtained results indicate that these gold 
nanoparticles do not exhibit any cellular toxicity. 
Next, we evaluated the pH-dependent cellular uptake of spherical gold nanoparticles 
coated with pHLIP® and PEG. The experiment was performed several times and in 
different ways, such that the treatment of cells with gold nanoparticles was done at 
neutral and low pH, or the pre-treatment of cells with gold nanoparticles was done at 
neutral pH followed by the change of pH with media to low pH. All obtained data 
indicate that the uptake of spherical gold nanoparticles coated with pHLIP® and PEG 




The results confirm the pH-dependent cellular uptake of gold nanoparticles coated with 
pHLIP® and PEG. 
 
3.4. Distribution of pHLIP® and PEG coated gold nanoparticles within tumors 
 
JC cancer cells were inoculated into the right flank of mice by subcutaneous injection. 
Spherical gold nanoparticles coated with pHLIP® and PEG were administered as a 
single intra-tumoral injection at quantities of 5.5 and 21 μg gold. One hour after 
injection, animals were sacrificed so that tumors could be collected and processed to 
establish the amount of gold within and the distribution throughout a tumor. Among 
all of the mice, there were animals with different tumor masses that were separated 
into 3 groups: 0.1, 0.3 and 0.4 g. The percentage of in jected dose accumulated within 
the tumors increased with the increase of tumor mass: 16.2% for 0.1 g tumor; 18.0% 
for 0.3 g, and 29.1% for 0.4 g of tumor (Supplementary Fig. S3). The mean tumor 
uptake of gold (calculated for 8 animals) was 6.8 μg of gold per gram of tumor (with 
standard error of 1.6) when a total of 5.5 μg of gold was injected. The mean tumor 
uptake of gold (calculated for 6 animals) was 24.5 μg/g (with standard error of 8.5) 
when 21 μg of gold was injected. The highest accumulation of gold  ∼47 μg/g was 
found in the smallest tumors (85.0 ± 2.3 mg) injected with 21 μg of gold.  
We also investigated the distribution of gold within the tumor mass. The white light 
images were taken from the center of the tumor mass (Fig. 4a). Then, the frozen tumor 
samples were sectioned and stained with H & E (Fig. 4b). The gold was distributed 
nearly homogeneously within tumor mass except the right edge of the tumor with no 
gold accumulation in the surrounding muscle. The muscle tissue adjacent to the tumor 




section containing both cancer cells and muscle is shown on Fig 4c. Adjacent sections 
were treated with Triton to permeabilize the cellular membranes and then stained with 
both a silver enhancement solution and DAPI. The representative images of the gold 




The motivation for our work was based on a desire to introduce stable pH-sensitive 
pHLIP® and PEG coated gold nanoparticles with a potential translation to the clinic. 
We developed methods for the preparation of spherical and multispiked gold 
nanoparticles coated with pHLIP® and PEG, which might find application in radiation 
and NIR thermal therapies. The approach for the synthesis of spherical gold 
nanoparticles coated with pHLIP® and PEG is very robust and can be implemented in 
applied studies. The protocol for the preparation of multispiked gold nanoparticles 
coated with pHLIP® and PEG could be further optimized, however the proof of 
principle is established in our work. In both cases, pHLIP® peptide and PEG polymer 
were used as components of the reducing solution (sodium citrate as a reducer in the 
case of spherical nanoparticles and ascorbic acid in the case of multi- spiked 
nanoparticles). The optimal combination of pHLIP® and PEG was selected to be 10% 
and 90%, respectively. A decreased percentage of pHLIP® in the nanoparticle coating 
might lead to the reduction of  particle stability (resulting from the reduction of the 
overall negative charge due to the presence of pHLIP® peptide on particle surfaces) 
and the loss of pH-dependent properties. Previously, we investigated and showed the 
utility of liposomes coated with different quantities of pHLIP® and PEG [30,35]. It is 




instead of directly coating the surface with pHLIP®. Spherical gold nanoparticles 
coated with pHLIP® and PEG exhibited high stability in solution over a one month  
time  period, as opposed to the particles with no coating or just PEG coating. The PEG 
coating was widely utilized in coating of various nanoparticles [42–46]. The size of 
the pHLIP® PEG coated particles’ metallic core was   in the range of 5–8 nm in 
diameter and the hydrodynamic size (diameter) of coated particles was in the range of 
40–50 nm. The nanoparticles showed a pH-dependent uptake by cancer cells with no 
signs of cytotoxicity. We performed intratumoral injections of spherical gold 
nanoparticle solutions and investigated gold uptake and distribution within tumors at 
one hour post-injection. It does not seem that there is any clinical utility to perform a 
systemic administration of particles, since radiation therapy is typically delivered 
locally and the location of the tumor is known from prior diagnostic imaging.  Also, 
there is a requirement to have as much gold as possible within a tumor (which could  
be achieved only by local administration of the particles) to induce a radiation 
enhancement effect. The radiation delivered within a one hour time frame of particle 
administration is expected to    be in line with clinical practice. Our results indicate 
that gold nanoparticles (21 µg of injected gold) were distributed within the tumor mass 
very well and with an overall uptake of 24.5 µg of gold per gram of tumor mass, 
reaching values of 47 µg/g in tumors with masses of 1 g and less. This is a higher 
uptake compared to that of pHLIP® gold nanoclusters [37]. We believe, the presence 
of pHLIP® peptide in the coating of gold nanoparticles was crucial. The peptide 
allowed particles to stay within the tumor and promoted the uptake of particles by 
cancer cells at low extracellular pH, as we have shown previously [37,38]. At the same 
time, particles were able to diffuse within a tumor as opposed to the direct injection of 




site [3]. We also would like to outline that systemic administration of nanoparticles or 
antibodies conjugated with gold nanoparticles results   in staining of only the peripheral 
tumor regions with limited penetration inside the tumor mass [47]. We did not observe 
an accumulation of gold within the muscle tissue adjacent to the tumors. The amount 
of injected gold in our study was much less than the amount of gold used in previous 
radiation therapy studies on mice (see review and references within it) [48]. However, 
we believe that the targeting of gold nanoparticles directed by pHLIP® peptide to the 
vital cellular structures such as plasma and nuclear membranes could lead to the 
enhancement of radiation effects even at lower gold concentrations [38].  
The spherical particles have the smallest surface to volume ratio for a given size of a 
particle. The appearance of multiple sharp spikes or tips on the surface of nanoparticle 
is known to give rise to the strong spatial confinement of the electromagnetic field, 
since the core of a particle serves as a nanoscale antenna, increasing the excitation 
cross section and the enhancement of the tip plasmon polaritons [49,50]. Various 
approaches were introduced in the synthesis of star-like and multispiked gold 
nanoparticles [50–53]. We used a soft template material of phospholipid bicelles to 
synthesize pHLIP® and PEG coated multispiked gold nanoparticles. Bicelles, which 
possess both low- and high- curvature regions within a bilayer disks, represent a class 
of model membranes used in nuclear magnetic resonance (NMR) structural studies of 
membrane biomolecules [41,54–56], but they have found additional applications in 
biomedical sciences [57–59]. The bicellar templates were utilized previously to control 
the growth of platinum with ascorbic acid as a reducer, producing metal nanodisks and 
nanowheels [60,61]. Other phospholipid structures, like spherical liposomes, were also 
used for gold deposition to assemble biodegradable plasmon resonant nanoshells, 




liposomes [62–64]. Another approach was based on the assembly of liposomes and 
micelles, called metallosomes, by using lipids conjugated with gold nanoclusters [65]. 
The presence of a soft template, like bicelles, in our reduction mixture induced the 
formation of multispiked gold nanoparticles with plasmon resonance in the NIR range. 
The absence of bicelles leads to the formation of spherical gold nanoparticles with 
absorbance at 525–560 nm. The size of gold multispiked nanoparticles established by 
TEM imaging and nanoparticle tracking system was in the range of 100–170 nm and 
130–200 nm, respectively. The heating of pHLIP® and PEG coated multispiked gold 
nanoparticles in solution by an 805 nm laser diode led to the increase of the solution 
temperature by 14 degrees within 5 min. Multispiked particles could be used in 
combination with NIR laser treatment for photo-induced hyperthermia. It would be 
very advantageous to employ lower power NIR laser radiation systems, which are 
currently available for indocyanine green (ICG) imaging in clinical endoscopy and 
laparoscopy (see table 4 for the description of IC G clinical imaging systems in the 
review article) [66]. Also, due to the very high surface area of multispiked gold 
nanoparticles, we envision their potential successful application for the enhancement 
of x-ray radiation effects. A number of binary radiation therapies are under 
consideration [2,67–69]. At low photon energies, the most promising approach is 
based on dose enhancement through Auger electron emission. Auger electron emission 
generates a cascade of low energy electrons that travel short distances and deposit their 
energy locally [70]. Thus, it is very important to deliver gold nanoparticles to vital 
cellular structures, which pHLIP® helps achieve. Also, it was proposed that a potential 
advantage of the use of small gold nanoparticles (with an enhanced surface/volume 




the gold nanoparticle [38,70]. Therefore, it could be very attractive to test multispiked 
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Figure 1. Characterization of Spherical Gold Nanoparticles. The absorbance spectra 
of the spherical gold nanoparticle solutions synthesized a) in the absence and presence 
of pHLIP® peptide and/or PEG polymer or mixture of 10% pHLIP® and 90% PEG 
(1.7% wt/vol citrate); b) with various amounts of sodium citrate, where the percentage 
of citrate is reported as the final wt/ vol concentration (10% pHLIP® and 90% PEG); 
c) with various amounts of pHLIP® and PEG (0.83% wt/vol citrate). d) The 
representative TEM images of pHLIP® and PEG coated spherical gold nanoparticles 
obtained at 20,000× and 40,000x magnifications (0.83% wt/vol citrate and 10% 
pHLIP®−90% PEG). The size histograms of the metallic core of pHLIP® and PEG 
coated nanoparticles  is shown  in Supplementary Fig. S2a. e) White light  images of 
particles at the beginning and end  of stability studies (0.83%  wt/vol citrate  and 10% 






Figure 2. Structure of bicelles. a) The disk-like shape of a bicelle with height, h, and 
radius, R, composed of DMPC and DHPC lipids. b) Dependence of bicelle size, 
established by DLS, on its q- value, which is a ratio of long- to short-chain lipids 






Figure 3. Characterization of Multispiked Gold Nanoparticles. a) The absorbance 
spectra of gold nanoparticles obtained by gold reduced with ascorbic acid, pHLIP®, 
and PEG in the absence and presence of bicelles of different asymmetries. b) The 
representative TEM image of pHLIP® and PEG coated multispiked gold nanoparticles 
obtained at 12,000× magnification. The size histograms of the metallic core of pHLIP® 
and PEG coated nanoparticles is shown in Supplementary Fig. S2b. c) The change in 
temperature over time measured in solutions containing pHLIP® and PEG coated 






Figure 4. Tumor Imaging of Spherical Gold Nanoparticle Uptake. a) The white light 
image of a tumor center showing the gold distribution (after a 21 μg intratumoral 
injection of pHLIP® and PEG coated spherical gold nanoparticles in PBS, pH7.4); b) 
the section from the tumor center stained with H & E; and c) the magnified image of 
the tumor section outlined by a square in panel b, which shows tumor (T) and muscle 
(M). The arrows on panels a and b indicate muscle tissue. d) The bright field image of 
tumor sections stained with silver enhancement solution and e) the fluorescent image 
of the same tumor section stained with DAPI to visualize cell nuclei; and f) an overlay 
of the bright filed and fluorescent images. The percentage of injected dose of gold 
accumulated within tumors of different masses is given in the text and in 
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Fluorescence imaging has seen enduring use in imaging blood flow and is now finding 
a new range of applications in image-guided surgery. In this paper, we report our 
studies of a new fluorescent agent for use in surgery, ICG-pHLIP. Intravenously 
administered ICG-pHLIP exhibits a multi-hour circulation half-life, offering 
protracted delineation of vasculature. Concomitant with blood clearance, ICG-pHLIP 
binds to cells in acidic tissues, such as tumors, by sensing cell surface acidity. 
Accumulation in tumors marks them for surgical removal or other treatments. We 
present the results of preclinical studies, including in vitro and in vivo efficacy, 
pharmacology and toxicology investigations.  It is found that ICG-pHLIP is non-toxic, 
marks blood flow for hours after injection, and effectively marks tumors for improved 
resection one day after administration. 
In this paper, we explore applications of a new fluorescent agent for use in surgery, 
ICG-pHLIP.  Fluorescence imaging has long had applications in imaging blood flow 
and is now finding a new range of applications in image-guided surgery. For decades, 
fluorescence angiography has been applied to assess blood flow and tissue perfusion 
in preoperative, intraoperative and postoperative settings1-8. Emerging uses in 
fluorescence-guided surgery promise to improve surgical outcomes by revealing tumor 
margins and, even more importantly, by marking flat lesions and micro-metastases 
adjacent to primary tumors, which are difficult to identify even by a very skilled 
surgeon9-12.  
Several FDA approved fluorescent dyes and compounds are now in clinical use. 5 -
Aminolevulinic acid (5-ALA) and its derivatives are heme precursors that induce 
production and intracellular accumulation of a fluorescent protoporphyrin. These dyes 




for fluorescent visualization of cancerous lesions in the bladder using blue light 
cystoscopy after topical application of the agent by intravesical instillation15-18. The 
most widely used dye is the near infrared (NIR) emitting indocyanine green (ICG), 
first approved for angiography and subsequently used in ophthalmology and elsewhere 
for imaging blood vessels19-24. In addition to clinically approved fluorescent 
molecules, several approaches are under development (in preclinical and clinical trial 
stages) for targeting and visualization of cancerous lesions intra- or post-operatively.  
We have introduced a novel imaging agent, ICG-pHLIP, for the visualization of 
cancerous lesions and blood flow during fluorescence-guided surgical procedures. A 
pH-Low Insertion Peptide (pHLIPs®1) senses elevated acidity at the surfaces of tumor 
cells (or low surface pH, pHsurf)25-27. Low pH promotes protonation of Asp/Glu 
residues within pHLIP, increasing the peptide’s hydrophobicity and triggering the 
peptide to form a stable helix across the membrane. By attachment to the N terminal 
end of the peptide, which remains outside the cell, imaging probes can be tethered to 
the surfaces of cells to mark tumors. Examples include PET or SPECT nuclear probes, 
MR agents and fluorescence emitters.  pHLIP offers a unique approach in the targeting 
of a spectrum of tumor subtypes, as acidosis is a fundamental feature of the tumor 
microenvironment28,29, and it has been found that pHLIP peptides conjugated with 
various fluorescent dyes target tumors with high precision 30. ICG coupled to pHLIP 
was chosen as a clinical candidate for two main reasons. The fluorescence of ICG-
pHLIP is enhanced about 20 times when pHLIP tethers ICG to the membrane 
compared to the emission of ICG-pHLIP in aqueous solution, thus significantly 
enhancing the tumor-to-background ratio31. Also, many clinical instruments for 
imaging of ICG fluorescence have already been developed and are clinically available, 
 




which potentially makes the adoption of ICG-pHLIP in the clinic a straightforward 
process. Here we present the results of preclinical studies, including in vitro and in 
vivo efficacy, pharmacology and toxicology investigations.  
 
RESULTS 
ICG-pHLIP Synthesis and Characterization 
The 28-amino acid pHLIP Var3 peptide with free N- and C-terminus was synthesized 
on solid support followed by purification and conjugation of a single Cys residue with 
ICG-maleimide to obtain the ICG-pHLIP imaging agent (Figure 1a, Supplementary 
Figure S1a). Further optimization of the ICG-pHLIP manufacturing protocol has been 
completed by CordenPharma, and GMP manufacturing is in progress. ICG-pHLIP 
reconstituted in PBS was found to be stable in solution for 4 days at room temperature.  
The molar attenuation coefficient (i.e. extinction coefficient) of ICG-pHLIP at 810 nm 
measured in methanol (Supplementary Figure S2a) was determined as 152,533 M -
1cm−1 and used to calculate the concentration of ICG-pHLIP. The absorption and 
emission spectra of ICG-pHLIP in DMF (to mimic the hydrophobic environment of 
the membrane) are shown in Figure 1b. It is important to note that spectral signals of 
ICG-pHLIP do not overlap with the absorption or emission of Methylene Blue and 
Isosulfan Blue, dyes which are widely used for tissue staining during surgery and for 
histological analysis (Supplementary Figure S2b-f). The interaction of ICG-pHLIP 
with membrane lipid bilayers was studied using POPC liposomes. ICG-pHLIP exhibits 
pHLIP-like pH-dependent interactions with cell membranes monitored by changes of 
the peptide circular dichroism and the fluorescence emission of tryptophan residues 
(Figure 1c-e). The midpoint of the transition for ICG-pHLIP insertion in liposomes is 




membranes with a cell surface pHsurf of 6.0 at equilibrium, while at the normal cell 
surfaces (pH 7.4) only <1% of ICG-pHLIP molecules might insert into membrane. 
Since the rate constant of ICG-pHLIP insertion into membrane is high (approximately 
5 sec-1) the insertion will occur even under conditions of fast blood flow and limited 
exposure time of  ICG-pHLIP to acidic cancer cells.  
 
Safety Studies In vitro 
The cytotoxicity of ICG-pHLIP was assessed by treatment of human mammary 
epithelial cells (HMEpC) with increasing concentrations of ICG-pHLIP (up to 16 µM) 
for 72 hours, followed by assessment of cell viability. ICG-pHLIP did not show any 
cytotoxic effect at any tested concentration.  
ICG-pHLIP interactions with components of the blood were investigated. It was 
established that >99.9% of ICG-pHLIP is bound at equilibrium in human, mouse, rat,  
minipig, dog and cynomolgus monkey blood, and that the amount of ICG-pHLIP 
bound to plasma proteins varies from 95.3% (mouse) to 99.9% (humans) 
(Supplementary Table S2). Hemolysis of red blood cells (RBCs) was followed with 
increasing concentrations of ICG-pHLIP (up to 1.2 nmol), and lysis was assessed by 
the release of hemoglobin.  The amount of RBC lysis was less than 2% in all samples.  
The rate of ICG-pHLIP hepatic clearance monitored using human, rat, dog, minipig 
and cynomolgus monkey hepatocytes was very similar, and varied from 20 -28 
µL/min/106 cells. The hepatic clearance established in the mouse hepatocytes, which 
are larger in size, was higher (42 µl/min/106 cells). In general, unbound ICG-pHLIP 
(not bound to serum proteins) exhibits a moderate rate of hepatic clearance.  
Safety pharmacology profiling of ICG-pHLIP (2 µM) was performed in vitro using 86 




observed on progesterone B, a nuclear receptor activated by the steroid hormone 
progesterone. A subsequent study of ICG-pHLIP’s interaction with progesterone B 
was used to establish IC50 and Ki for ICG-pHLIP to be 0.64 µM and 0.51 µM, 
respectively (for comparison, the IC50 and Ki for the known R-2050 progesterone 
agonist are several fold lower, 0.33 nM and 0.26 nM, respectively, Supplementary 
Figure S3). It is unlikely that a significant amount of ICG-pHLIP would reach the 
nucleus after a single i.v. administration of the agent, since it binds to cellular 
membranes.  
The genotoxicity of ICG-pHLIP was evaluated using in vitro bacterial reverse 
mutation and mammalian cell micronucleus tests in human peripheral blood 
lymphocytes (see details in Supplementary Information). ICG-pHLIP did not show 
any evidence of genotoxic activity in these in vitro mutagenicity assays. 
 
Animal Studies 
All animal work performed at the University of Rhode Island, the Stryker Corporation, 
the Memorial Sloan Kettering Cancer Center (MSKCC) Antitumor Assessment Core 




Pharmacokinetic studies were performed on mice and dogs. Blood samples were 
collected at 5, 15, 30 min and 1, 2, 4, 6, 8, 12 or 16, 24 and 48 h after a single i.v. dose 
of ICG-pHLIP (12.3 mg/kg to mice and 0.064 mg/kg to dogs). Evidence of systemic 
exposure to ICG-pHLIP was observed in all animals and was quantifiable up to 8-16 




observed in both cases (Figure 1f, g). The mean clearance (Cl), volume of distribution 
(Vz) and elimination half-time (T1/2) values obtained for mice and dogs were very 
similar: Cl = 9.53 mL/h/kg (mice) and 11.6 mL/h/kg (dogs); Vz = 53.51 mL/kg (mice) 
and 61.6 mL/kg (dogs); and T1/2 = 3.9 h (mice) and 3.7 h (dogs).  
 
Blood Vessel Imaging   
Our data show that ICG-pHLIP has a strong affinity to plasma proteins resulting in a 
relatively slow blood clearance: the agent remains at significant levels in the blood for 
several hours. These are essential features of a good blood pool agent for fluorescence 
angiography. Free ICG is currently used as a contrast agent for imaging blood flow, 
and it also binds to plasma proteins; however, it is cleared from the blood within a few 
minutes, allowing only a limited time window for imaging. We carried out a 
comparative study of blood flow imaging using ICG-Cys (ICG-maleimide conjugated 
with a Cys residue) and ICG-pHLIP (2.5 nmol of each). As expected, ICG-Cys was 
cleared from the blood within the first 5 min (Figure 2a), whereas ICG-pHLIP clearly 
revealed the blood vessels for up to 2 hours (Figure 2b and Supplementary Figures 
S4). To further investigate the potential utility of ICG-pHLIP in fluorescence 
angiography, blood perfusion was imaged in pigs, since the blood circulation of pigs 
is closely related to that of humans. The pig received several doses of ICG-pHLIP: 
0.052 mg/kg (dose 1) followed by additional 0.12 mg/kg (dose 2) and then followed 
by additional 0.24 mg/kg (dose 3). Visualization of ICG-pHLIP NIR fluorescence in 
blood vessels was performed using two systems: i) for endoscopic/laparoscopic 
imaging inside the pig body cavity (Figure 3a, Supplementary Figure S5a and 
Supplementary Video S1), and ii) open field imaging of a pedicle flap (Figure 3b, 




clearly visible at 2 hours post-injection (Supplement Figure S5), establishing the 
superiority of ICG-pHLIP use over ICG in fluorescence angiography and other blood 
flow/perfusion applications. 
 
Biodistribution and Tumor Targeting 
Biodistribution and tumor targeting were followed after a single tail vein injection of 
ICG-pHLIP in mice bearing murine and human tumors. Biodistribution studies were 
carried out in female and male mice bearing a triple negative 4T1 tumor, which closely 
mimics stage IV of human breast cancer. Targeting of 4T1 tumors in BALB/c mice by 
ICG-pHLIP is shown in Supplementary Figure S6. To establish the biodistribution of 
ICG-pHLIP, animals were euthanized at different time points (5 min, 1, 2, 4, 6, 16, 26 
and 48 h), organs were collected and imaged. Representative images of organs are 
shown in Figure 4a (values of fluorescence intensity are shown in Supplementary 
Table S4 and mean values are given in Supplementary Table S5, the calculated signal 
level in each organ at different time points is shown in Supplementary Figure S7). The 
kinetics of fluorescence signal changes in organs and tissue is shown in Figure 4b -g. 
Organs and tissues were frozen after imaging and processed to measure the signal in 
the tissue/organ homogenates. It is challenging to establish precisely the amount of 
fluorescent compound in the tissue and organs. However, we made rough estimations 
using a calibration curve, which was obtained by spiking known amounts of ICG-
pHLIP with organs and tissue homogenates collected from control animals. According 
to our estimates the amount of ICG-pHLIP within the tumor reaches about 10-15% 
ID/g at 4 hours post injection and stays constant up to 24 h, decaying slightly at 48 h. 
The clearance was observed to be predominantly hepatic, and the level of the signal 




administration, followed by the decay of the signal after 6 hours. Well-perfused organs 
like the heart, kidney and lungs were imaged as is (no perfusion with buffer), and it is 
evident that a significant amount of the signal (especially at earlier time points) is 
coming from the blood associated with these organs, and that the level of the signal 
decays with blood clearance. Another group of organs, such as spleen, pancreas, 
stomach and brain have a lower signal level, which also decays with blood clearance. 
Small and large intestines, bone, skin and muscle (and prostate in male animals, not 
shown here) have very low signal levels, estimated to be less than 2% ID/g at all time 
points. At 20-48 h, when the blood is cleared and the fluorescence signal in all organs 
is minimal, the contrast between tumor and surrounding tissue or healthy organs is 
very significant. 
 
ICG-pHLIP tumor targeting was observed in several tumor models of breast (MDA -
MB-231 human and 4T1 murine), lung (A549 human and LLC murine), epithelial 
(melanoma) (M4A4 human), cervical (HeLa human), urinary bladder (UM-UC3 
human) and prostate (LNCaP human) cancers. NIR fluorescence imaging on live 
animals using the Stryker clinical imaging system was performed at 24 h after a single 
i.v. administration of ICG-pHLIP (Supplementary Figure S8). To closely mimic the 
conditions of intraoperative imaging, during which fluorescence is monitored from 
exposed tissue, the skin was removed from the tumor side while animals were under 
anesthesia. Excellent tumor targeting by ICG-pHLIP was seen, and small, medium and 
large tumors positioned deep in tissue or exposed at the surface, including small nearby 
micro-metastases, were clearly seen (representative images are shown in Figure 5). To 
further examine the contrast between tumor and normal tissue, the tumors were 




muscle in most cases was evidently visible and was defined  with high precision by the 
fluorescence signal. To correlate the ICG-pHLIP NIRF signal with tumor location, the 
tumor-muscle pieces were frozen immediately following NIRF imaging, sectioned, 
fixed and stained with hematoxylin and eosin (HE). An excellent correlation between 
ICG-pHLIP imaging and HE histopathology in locating the tumors is shown in Figure 
7 and Supplementary Figure S9. Fluorescent (non-processed) and HE stained sections 
were examined via an IR scanner and optical microscope. Tumors (marked as T) and 
surrounding stroma (marked as S1, S2 and S3) exhibit ICG-pHLIP NIR fluorescent 
signal, as opposed to the muscles (marked as M1 and M2), which have little signal. 
Cancer cells infiltrating into surrounding muscles are clearly seen in magnified images 
of stroma. The ability of ICG-pHLIP to stain a tumor mass as well as surrounding 
tissues with infiltrating cancer cells is expected to aid improved margin resection 
during surgery. 
 
Fluorescence-Guided Tumor Resection   
Murine breast cancer 4T1 and human cervical HeLa tumors were implanted into 
athymic female nude mice. ICG-pHLIP was given as a single i.v. injection at doses 
0.5, 1.25 and 2.5 mg/kg.  Surgeries were performed 24 and 48 h after injection under 
fluorescence guidance using a Stryker SPY-PHI handheld clinical instrument, which 
will be used in breast cancer surgical clinical trials for imaging of ICG-pHLIP. The 
images and video obtained during the procedure are shown in Figure 8 and 
Supplementary Video S3. 
 




The animal efficacy studies indicated that a dose of 0.5 mg/kg of ICG-pHLIP gives 
satisfactory imaging, which corresponds to 0.04 mg/kg human dose (h.d.). Toxicology 
studies were performed assuming the minimum human dose (h.d.) to be 0.04 mg/kg 
(the details of these studies can be found in the Section “Pharmacology and Toxicology 
Studies” Supplementary Information). In summary, the following GLP studies were 
carried out and no adverse effects were observed: 
Single-dose and 7-days repeat i.v. toxicity in beagle dogs: ICG-pHLIP was 
administered by single i.v. bolus injection at 0.063 mg/kg (0.85× h.d. recalculated for 
dog dose), 1.08 mg/kg (15× h.d.), 2.16 mg/kg (30× h.d.) or once daily for 7 days at 
2.16 mg/kg/day (30× h.d. per day) to dogs, and did not adversely affect the overall 
health or condition of the animals, any of the measured clinical pathology parameters, 
organ weights, macroscopic or microscopic pathology. Based on these results, the no -
observed-adverse-effect level (NOAEL) was 2.16 mg/kg/day (30× h.d. per day) in 
males and females.   
7-day repeat i.v. toxicity in B6D2F1 mice: ICG-pHLIP was administered once daily 
for 7 days at 4.92 mg/kg/day (1× h.d. per day), 7.38 mg/kg/day (15× h.d. per day) and 
12.3 mg/kg/day (25× h.d. per day). The repeat administration of ICG-pHLIP did not 
result in any signs of systemic or delayed toxicity in male and female mice.  
A cardiovascular telemetry study in unrestrained, conscious non-naïve beagle dogs: 
A single administration of ICG-pHLIP at dose levels of 0.072 mg/kg (1× h.d.), 0.36 
mg/kg (5× h.d.), and 1.44 mg/kg (20× h.d.) to male dogs resulted in no effect on 
systemic blood pressures, heart rate, body temperature, electrocardiographic intervals, 
or qualitative ECG parameters up to 24 hours post-dose.  
Local tolerance/irritancy in New Zealand white rabbits: A single administration of 




all routes of administration was well tolerated and did not result in any ICG-pHLIP 
related changes. 
A pharmacological safety assessment on the central nervous system in Sprague 
Dawley rats: A single administration of ICG-pHLIP at dose levels of 0.218 mg/kg 
(0.88× h.d.), 0.248 mg/kg (1× h.d.), 3.72 mg/kg (15× h.d.) and 7.44 mg/kg (30× h.d.) 
had no effect on the central nervous system up to 24 h post-dose. 
Micronucleus test in Sprague Dawley rats: A single administration of ICG-pHLIP at 
dose levels of 6.25 mg/kg (25× h.d.), 12.5 mg/kg (50× h.d.) and 25 mg/kg (100× h.d.) 
showed no evidence of genotoxic activity. 
 
Discussion 
The clinical use of ICG fluorescence imaging is growing and has stimulated the 
production of a large variety of instruments for open, endoscopic and lap aroscopic 
surgical procedures32. Following intravenous injection, ICG is rapidly bound to plasma 
proteins, with minimal leakage into the interstitium. The blood half -life is 2.5 min33,34.  
There are no known metabolites. ICG is rapidly extracted by the liver without 
modification and nearly exclusively excreted by the liver, appearing unconjugated in 
the bile approximately 8 min after injection, depending on liver vascularization and 
function20. When injected outside blood vessels, ICG binds to proteins and is found in 
the lymph, reaching the nearest draining lymph node usually within 15 min, and after 
1–2 h, it binds to the regional lymph nodes, deposited into macrophages 35,36. The 
intravenous injection dose of ICG typically varies in the range from 0.5 mg/mL/kg to 
2.0 mg/mL/kg of body weight. No significant acute toxic effects have been observed 
in humans at a high dose of 5 mg/kg of body weight20, and chronic toxicity has not 




Even though fluorescence-guidance using ICG allowed improvement of surgical 
procedures there remain several important limitations associated with the use of ICG. 
ICG (as any non-targeted small molecule including fluorescent dye) has no strong 
accumulation within tumors except a weak signal from enhanced permeation retention 
(EPR) in vascularized tumors. ICG may be taken up by some cancerous lesions only 
if the blood flow uptake is enhanced for the particular lesion. In other cases, ICG has 
been used to visualize a lesion via a lack of signal, where the uptake/signal of ICG was 
much lower within the lesion compared to the surrounding tissue 37. However, ICG, 
does not have any inherent tumor-targeting properties based on selective binding. Also, 
the use of ICG for blood-flow visualization is limited by its very fast blood clearance 
profile, which requires sometimes multiple injections during the same surgical 
procedure. ICG-pHLIP resolves these deficiencies.  
Tumor targeting by pHLIP has been well-documented in a large variety of animal 
tumor models and human tissues. ICG-pHLIP was  used to image cancerous lesions in 
human bladders31 and the human upper urinary tract38.  The agent was applied ex vivo 
after the surgical removal of organs, followed by washing and NIR fluorescent imagi ng 
using clinical imaging instruments. Bladder malignant lesions were targeted by ICG-
pHLIP, identified by NIR imaging and shown by pathology to have a sensitivity of 
97% and specificity of 100%. Carcinoma in situ was accurately diagnosed in 11 cases, 
whereas only four of these cases were seen using white light. All malignant upper tract 
lesions were targeted by ICG-pHLIP and visualized on NIR imaging with a sensitivity 
of 100% (compared to 78.9% white light imaging) and a specificity of 100%. Benign 
collecting systems and ureters did not show uptake of the pHLIP construct. 
Fluorescent pHLIP peptides were also used in applications to other human tissues for 




Taken together, the published work on the mechanism of pHLIP action, on tumor 
targeting and visualization, as well as in the preclinical studies with the ICG-pHLIP 
presented here, including PoC, pharmacology and toxicology assessments, motivate 
the clinical translation of ICG-pHLIP for systemic administration for i) real-time blood 
flow visualization and ii) targeting and identification of cancerous lesions during 
surgical procedures. The agent will be initially evaluated in a first-in-human trial on 
breast cancer patients, which will combine advanced pre-operative multiparametric 
MRI for the comprehensive assessment of tumor microenvironment including tumor 
acidity with intra- and post-operative NIR fluorescent imaging, standard 
histopathological and molecular profiling analysis. It is expected that ICG-pHLIP 
might allow accurate identification of tumor margins, targeting and visualization of 
flat lesions and the identification of micro-metastasis nearby a primary tumor mass, 
which are difficult to establish by the naked eye or white light imaging. Further, real 
time blood flow imaging with ICG-pHLIP is expected to significantly extend the 
imaging time window from several minutes to several hours, allowing imaging to be 
performed any time during a surgical procedure after a single injection of the agent. 
Potentially, multi-color imaging could be developed: ICG-pHLIP could be used to 
visualize blood vessels, and pHLIP with a fluorescent dye emitting in the range of 600 -
700 nm could be used for tumor imaging, allowing imaging of cancerous lesions and 
blood vessels during the same surgical procedure. 
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Figure 1. Characterization of ICG-pHLIP and blood clearance in mice and dogs. 
(a) The Var3 pHLIP sequence is shown with the chemical structure of the ICG dye 
coupled to a single Cys residue at the N-terminal part of pHLIP. (b) Normalized 
absorbance (black line) and fluorescence (red line) spectra (the excitation is at 805 nm) 
of ICG-pHLIP (5 µM) measured in DMF. (c) Circular dichroism (CD) spectra of ICG-
pHLIP measured in phosphate buffer (pH8) in absence (ICG-pHLIP, pH8 – black line) 
and presence  (ICG-pHLIP + PC, pH8 – blue line) of POPC liposomes, and in the 
presence of POPC liposomes at pH5.2 (ICG-pHLIP + PC, pH5.2 – red line). (d) pH-
dependent insertion of ICG-pHLIP into the bilayers of POPC liposomes monitored by 
changes of the CD spectral signal at 222 nm. The data were fitted with the Henderson -
Hasselbach equation (red line with 95% confidence interval) to establish the midpoint 
of the transition (pK). (e) The kinetics signal (multiplied by -1) of ICG-pHLIP insertion 
into lipid bilayers of POPC liposomes as a result of a pH drop from pH8 (blue line in 
insert) to pH5 (red line in insert) was monitored in real-time by the tryptophan 
fluorescence changes (black line). The gray line is a baseline obtained by mixing ICG-
pHLIP with POPC liposomes at pH8 with pH8 buffer. The red line is a bi-exponential 
fit of the experimental data (85% of the signal changes occur with a rate of 5 sec-1 and 
about 15% of final adjustment is completed at a rate of 0.077 sec -1). (f-g) Blood 
clearance profile and single exponential fitting curves (red lines) obtained on mice ( f) 
and dogs (g) after a single i.v. injection of 12.3 mg/kg of ICG-pHLIP to mice and 0.064 





Figure 2. Imaging of blood vessels in mice. Representative NIR ICG-pHLIP 
fluorescent images of blood vessels at different time points after a single i.v. injection 
of ICG-Cys (a) or ICG-pHLIP (b).  
 
Figure 3. Imaging of blood vessels in pigs. Representative NIR ICG-pHLIP 
(verification batch #1912127) fluorescent images and overlay of fluorescent and color 
images of blood vessels at different time points after injection of ICG-pHLIP in PBS 
(dose 1 - 0.052 mg/kg; dose 2 - additional 0.12 mg/kg; dose 3 - additional 0.24 mg/kg) 
are shown. (a) Imaging inside the pig body cavity was performed using a Stryker 1688 
AIM system (808 nm excitation) for endoscopic/laparoscopic imaging (gain 8/10 for 
dose 2, gain 7/10 for dose 3). (b) Imaging of a pedicle flap was performed using a 
Stryker SPY-PHI handheld device (805 nm excitation) for open field imaging. 
 
Figure 4. Biodistribution and kinetics. (a) Representative NIR ICG-pHLIP 
fluorescent and photo images of tumor, major organs and tissues obtained at different 
time points are shown after a single i.v. administration of ICG-pHLIP into BALB/c 
female mice bearing murine 4T1 breast tumors in right flanks. Tissues and organs were 
imaged immediately after necropsy. The values of the fluorescence signal obtained for 
all female mice are presented in Supplementary Tables S4 (the NIR fluorescent sign als 
obtained in male mice were similar, data are not shown).  (b-g) The calculated mean 
and standard deviation values at different time points post-dose are shown. The values 
are given in the Supplementary Table S5. The description of %ID/g calculations is  





Figure 5. Tumor targeting. Representative photos and overlay of photos and in vivo 
NIR ICG-pHLIP fluorescent images of athymic female nude mice bearing murine and 
human tumors are shown with skin removed f rom the tumor site. The imaging was 
performed at 24 hrs after a single i.v. administration of ICG-pHLIP. Arrows indicate 
tumor locations.  
 
Figure 6. Ex vivo imaging of tumors with surrounding muscle. Representative 
photos, and overlays of photos and ex vivo NIR ICG-pHLIP fluorescent images of 
tumors resected with surrounding tissue immediately after in vivo imaging. 
 
Figure 7. Ex vivo imaging and imaging of sections. (a) Representative images of 
tumors with surrounding tissue: photos, NIR ICG-pHLIP fluorescent images, overlay 
of photos with NIR ICG-pHLIP fluorescent images, and images of HE-stained sections 
obtained from the same tumor-muscle pieces are shown. (b) Bright field image of HE-
stained section and NIR ICG-pHLIP fluorescent images of the adjacent non-processed 
section obtained on IR scanner shown in monochrome (green) and 16-color (white and 
red are the highest intensity, and black and dark blue are the lowest intensity) 
presentations. T indicates tumor; M indicates muscle, and S indicates stroma. (c) 
Magnified bright field images (using 20x objective) of tumor (T), muscle (M1 and 
M2), stroma (S1, S2 and S3) of HE-stained section are presented in panel b.  
 
Figure 8. Surgical removal of tumors under fluorescence guidance . Representative 
overlay of color and NIR ICG-pHLIP (verification batch #1912127) fluorescent 































































ICG-pHLIP for delineation of tumors and blood flow  
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METHODS 
Manufacturing of ICG-pHLIP 
All manufacturing procedures were completed in accordance with good laboratory 
practice (GLP) quality control specification. Synthesis of ICG-pHLIP (NH2-Ala-Cys-
Asp-Asp-Gln-Asn-Pro-Trp-Arg-Ala-Tyr-Leu-Asp-Leu-Leu-Phe-Pro-Thr-Asp-Thr-
Leu-Leu-Leu-Asp-Leu-Leu-Trp-Ala-COOH) acetate salt (C204H283N39O50S2, M.W. 
4,145.8 g/mol) was developed and the agent was produced by Iris Biotech, GmbH 
(Germany) in partnership with Chemical and Biopharmaceutical Laboratories (CBL) 
(Greece). The pHLIP peptide was synthesized on a solid support, followed by 
purification using HPLC. ICG-malemide was synthesized in solution, followed by 
column purification. ICG-malemide was conjugated with the pHLIP peptide in 
solution followed by purification of the final product (ICG-pHLIP) using HPLC. 
Seven grams (7 g) of ICG-pHLIP were produced with a purity of 98.7% established 




the synthesized ICG-pHLIP was 1383.0 Da [M+3H]3+/3 ± 1 and the expected 
theoretical mass is 1382.9 Da [M+3H]3+/3) was used in proof of concept (PoC), 
toxicology and pharmacokinetics studies. Manufacturing of ICG-pHLIP and analytical 
characterization were further optimized by CordenPharma, GmbH (Germany). 
TheHPLC analytical method developed for the detection of ICG-pHLIP is the 
following: HPLC column is Waters, BEH C8, 150 x 2.1 mm, 1.7 µm particle size; 
temperature is 33°C; injection volume is 1.2 µL; eluent A is water + 0.04% TFA; eluent 
B is CH3CN + 0.04% TFA; flow rate is 0.4 mL/min; detection wavelength is 220 nm; 














A spiking experiment was used to compare the ICG-pHLIP product obtained after 
optimization of the manufacturing process with previously produced material. Both 
ICG-pHLIP products were mixed in a ratio of 1:1 and analyzed by HPLC (Figure S1b). 
The presence of a single signal on the HPLC chromatogram confirms the identity of 




by UHPLC-MS. The analysis provided a m/z-ratio of 1381.96 Da [M+3H]3+/3 (Figure 
S1c). GLP ICG-pHLIP verification batch #1912127 was manufactured in Frankfurt by 
CordenPharma, the acceptance criteria are presented in Supplementary Table S1.  
 
Stability Study 
Stability studies were performed with ICG-pHLIP formulations in PBS and PBS 
containing 5% DMSO or 5% Ethanol (vol/vol). The tumor targeting capability in mice 
is independent of formulation. Formulation of ICG-pHLIP in PBS/5% Ethanol was 
used in PoC animal studies, and in toxicity studies on mice, rats and dogs. For the 
PBS/5%DMSO formulation 1 mg of the lyophilized powder of ICG-pHLIP was 
dissolved in 75 µl of DMSO (to make 3.2 mM solution), then 10 µl of 3.2 mM stock 
was mixed with 190 µl PBS to make a 0.16 mM solution of ICG-pHLIP (5% DMSO). 
For the PBS/5%Ethanol formulation, the lyophilized powder of ICG-pHLIP was 
dissolved at concentration of 1.6 mg/ml in PBS/5% Ethanol solution. Finally, the 
formulation selected for human use the was prepared by dissolving the lyophilized 
powder of ICG-pHLIP at a concentration of 0.8 mg/ml in PBS. All formulations were 
kept at room temperature and protected from light. The aliquots were taken at 0.5 or 
1, 3, 6, 24, 48 and 72 hours (102 hrs for ICG-pHLIP dissolved in PBS) for analytical 
HPLC analysis using a Zorbax SB-C18 column (4.6 x 250 mm, 5 µm) with a binary 
solvent system using a 15-85% water and acetonitrile gradient with 0.05% TFA over 
25 min. All formulations demonstrated stability (>95% purity) up to 72 hours when 
kept at room temperature. Formulation of ICG-pHLIP in PBS was stable in solution 







POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, Avanti Polar Lipids, Inc.) 
liposomes were used in biophysical measurements to mimic cells, and to investigate 
ICG-pHLIP interaction with lipid bilayers.  Large unilamellar vesicles (LUVs) were 
prepared by extrusion. POPC dissolved in chloroform was desolvated in a rotary 
evaporator and placed under high vacuum for 2 hours to create a phospholipid film. 
Lipids were then rehydrated in phosphate buffer (pH8) and repeatedly extruded 
through membranes with a pore size of 100 nm to make LUVs.  
 
Absorbtion and Emission Measurements 
Absorbtion spectra of ICG-pHLIP, Methylene Blue (MB) and Isosulfan Blue (IB) in 
PBS, methanol, DMSO or DMF were measured in a cuvette with 1 cm path length 
using a Genesys 10S UV-Vis (Thermo Scientific) spectrophotometer. Fluorescence 
spectra of ICG-pHLIP (with an excitation of 295 nm to record tryptophan fluorescence 
of pHLIP, and 805 nm to record ICG fluorescence), MB (with an excitation of 670 
nm) and IB (with an excitation of 630 nm, the fluorescence was insignificant) were 
measured in aqueous solution (in the presence or absence of POPC liposomes in the 
case of ICG-pHLIP), methanol, DMSO or DMF using PC1 (ISS, Inc) and SpectraMax 
M2 (Molecular Devices) spectrofluorometers. 
 
Calculation of Molar Attenuation Coefficient 
Different amounts of ICG-pHLIP (1.85, 1.808, 3.90, 4.15, 4.191, 7.16 and 7.19 mg) 
were weighed and dissolved in 2 ml of methanol followed by 25x or 50x further 
dilution in methanol for measurements of absorbance spectra (each spectra were 




was ensured that the absorbance was zero at 900 nm. All spectra were normalized and 
adjusted for the peptide content in the sample. The OD reading at 810 nm was used to 





where c is the concentration of ICG-pHLIP calculated by weight and l is the optical 
path of the cuvette (1 cm). The mean molar attenuation coefficient for ICG-pHLIP in 
methanol at 810 nm was established to be 152,533 ± 5,225 M-1 cm-1. 
 
Circular Dichroism and pH-Dependence 
Circular dichroism (CD) measurements were employed to monitor the pH-dependent 
insertion of ICG-pHLIP into the membrane of POPC liposomes and the formation of 
helical structure. CD measurements were performed using a MOS-450 spectrometer 
(Biologic, Inc) with its temperature control set to 25.0°C. CD spectra were recorded 
from 200 to 260 nm with steps of 1 nm. The pH-dependent insertion of ICG-pHLIP 
into the lipid bilayer of POPC liposomes was studied by monitoring the changes in the 
molar ellipticity (measured in millidegrees) at 222 nm as a function of pH.  After the 
addition of aliquots of citric acid, the pHs of solutions containing 5  μM ICG-pHLIP 
and 750 µM POPC liposomes were measured using an Orion PerHecT ROSS 
Combination pH Micro Electrode and an Orion Dual Star pH and ISE Benchtop Meter 
before and after each spectrum measurement to ensure that equilibrium is achieved. 
The ellipticity millidegrees were plotted as a function of pH. The pH-dependence was 
fit with the Henderson-Hasselbalch equation (using OriginLab software) to determine 
the cooperativity (𝑛) and the mid-point (𝑝𝐾 ) of a transition:   









To follow ICG-pHLIP insertion into the lipid bilayer of POPC liposomes in real-time, 
kinetics measurements were performed using a SFM-300 mixing system (Bio-Logic 
Science Instruments) in combination with a MOS-450 spectrometer with its 
temperature control set to 25.0°C. ICG-pHLIP pre-mixed with POPC liposomes at 
phosphate buffer at pH8 were mixed (dead time is 5 ms) with acid to drop the pH from 
pH8 to pH5 and promote pHLIP insertion into the bilayers. The insertion process was 
monitored by recording changes of the tryptophan fluorescence of pHLIP excited at 
295 nm and using a cut off filter at 320 nm.  
 
Cytotoxicity 
Human mammary epithelial cells (HMEpC) acquired from Cell Applications, Inc. 
were authenticated and stored according to supplier’s instructions. Cells were cultured 
in mammary epithelial cell growth medium provided by manufacturer. HMEpC cells 
were loaded in the wells of 96-well plates (~6,000 cells per well) and incubated 
overnight. Increasing amounts of ICG-pHLIP dissolved in cell growth medium were 
added to cells to give the following final concentrations of ICG-pHLIP with cells: 
0.125, 0.25, 0.5, 1, 2, 4, 8 and 16 μM. After 48 and 72 hours of incubation, a 
colorimetric reagent (CellTiter 96 AQueous One Solution Assay, Promega) was added 
for 2 hours followed by measuring absorbance at 490 nm to assess cell viability. All 






Whole Blood and Plasma Binding Assays 
Whole blood and plasma binding assays were performed by Cyptotex  US, LLC using 
human, mouse, rat, minipig, dog and cynomolgus monkey blood samples. ICG-pHLIP 
or ICG (5 µM) was added to whole blood or plasma or PBS and dialyzed in a rapid 
equilibrium dialysis device (with 8 kDa cut off) against PBS. Both fractions were 
processed and analyzed. Solution of water/NaCl/ascorbic acid (100/37/0.5 v/w/w) and 
ACN/MeOH (50/50 v/v) were used to precipitate proteins, followed by evaporation of 
the eluent, dry and reconstitution of samples for LC-MS/MS analysis on SCIEX 6500 




where A^ is Alanine(13C3,15N); L^ is Leucine(13C6,15N); R^ is Arginine(13C6, 15N4); 
Cam is Cysteine-carbamidomethylation, synthesized and purified by New England 
Peptides, Inc was used as internal standard (IS). 
 
Hepatocyte Stability Assay 
Hepatocyte stability (clearance) assays were performed by Cyptotex US, LLC using 
human, mouse, rat, minipig, dog and cynomolgus monkey pooled cryopreserved 
hepatocytes. ICG-pHLIP was incubated with hepatocytes at 37°C for different period 
of times: 0, 10, 20, 40 and 60 min (for mouse hepatocytes) and at 0, 15, 30, 60 and 120 
min (for human, mini pig, rat, dog and cynomolgus monkey hepatocytes). Hepatocytes 
(100 µL of concentration 0.5x106 cells cells/mL) and stock solvent (PBS/EtOH, 95/5 
v/v) spiked with 1 µM ICG-pHLIP along with unspiked hepatocytes and stock solvent 




and ACN/MeOH (50/50 v/v) were used to precipitate proteins, followed by 
evaporation of the eluent, dry and reconstitution of samples for LC-MS/MS analysis. 
The data were calculated as % parent remaining by assuming zero minute time point 
peak area ratio (analyte/ pHLIPIS) as 100% and dividing the remaining time point peak 
area ratios by zero minute time point peak area ratio. Data were fitted to a first-order 
decay model to determine the half -life. From the logarithmic plot of peak area against 
time, the slope was determined, where the (-slope) equals the elimination rate constant 
(𝑘). The half-life (𝑡1/2 ) equals 0.693/ 𝑘  and the intrinsic clearance (𝐶𝑙 𝑖𝑛𝑡) (ml/min/10 6 







where 𝑉 equals the ratio of the incubation volume (ml) to the number of cells.  
 
Hemolysis assay 
Single donor human whole blood was purchased from Innovative Research, Inc. Red 
blood cells (RBCs) were collected by centrifugation of whole blood at 2000 rpm for  
10 minutes followed by washing three times with Dulbecco’s PBS (DPBS) and re -
suspended in DPBS at a concentration of 7.5% (vol:vol). Varying concentrations of 
ICG-pHLIP (0.075, 0.15, 0.3, 0.6, 1.2 nmol) in DPBS were added to RBCs to give a 
5% RBC suspension (the total volume of the solution with RBC was 150 µL). The 
resultant mixtures were incubated at 37°C for 2 hours and then centrifuged at 1500 
RCF (~3000 RMP) for 10 min. Hemolysis was assessed by the release of hemoglobin, 




hemoglobin. DPBS was used as a negative control. As positive controls, which result 
in 100% lysis of RBCs, we used i) water and ii) 10% of Triton X-100. The percentage 
of hemolysis was calculated as follows:  




where, ODTest, ODNC, and ODPC are the optical density reading (absorbance) values of 
the test sample, negative control and positive control, respectively. The assay was 
performed in triplicate. The amount of RBC lysis was less than 2% in all samples. For 
reference, in a mouse study 2.5 nmol of ICG-pHLIP is injected per mouse (a 20-25 g 
mouse has about 1.2 mL of blood), or 2.08 nmol/ml (the dose in humans is much 
lower), while in a hemolysis assay the maximum tested concentration was 8 nmol/ml. 
 
Enzyme Binding Assay 
The ICG-pHLIP enzyme binding assays were performed by Eurofins Panlabs, Inc. 
according to standard assay protocols. The following enzymes were used in the binding 
assay with 2 µM of ICG-pHLIP: acetyl cholinesterase; peptidase (angiotensin 
converting enzyme); ATPase (Na+/K+, pig heart); CTSG peptidase (cathepsin G); 
cyclooxygenases COX-1 and COX-2; monoamine oxidases MAO-A and MAO-B; 
phosphodiesterases PDE3 and PDE4D2; protein tyrosine kinase (insulin receptor); 
protein tyrosine kinase (LCK); protein serine/threonine kinase (PKC, non-selective); 
adenosine A1 and  A2A; adenosine transporter; adrenergic α1A, α1B, α1D, α2A, α2B, 
β1 and β2; norepinephrine transporter (NET); androgen (testosterone); angiotensin 
AT1; bradykinin B2; calcium channels L-type (benzothiazepine, dihydropyridine, 
phenylalkylamine); calcium channel N-type; cannabinoid CB1 and CB2; chemokine 
CCR1; cholecystokinin CCK1 (CCKA) and CCK2 (CCKB); dopamine D1, D2L and 




transporter; GABAAs (flunitrazepam, central; Ro-15-1788, hippocampus and chloride 
channel, TBOB); glucocorticoid; glutamate (AMPA, kainate, agonism NMDA, 
glycine NMDA, phencyclidine NMDA, polyamine NMDA, and mGlu5 
metabotropic); glycine (strychnine-sensitive); histamine H1 and H2; chemokine 
CXCR2 (IL-8RB); cysteinyl leukotriene (CysLT1); melanocortin MC1 and MC4; 
muscarinic M1, M2, M3, and M4; tachykinin NK1; neuropeptide Y Y1; nicotinic 
acetylcholine α1 (bungarotoxin) and α3β4; opiate δ1 (OP1, DOP), κ (OP2, KOP), and 
μ (OP3, MOP); platelet activating factor (PAF); potassium channels (KATP and  
hERG); PPARγ; serotonin (5-hydroxytryptamine) 5-HT1A, 5-HT1B, 5-HT2A, 5-
HT2B, 5-HT2C, and 5-HT3; serotonin transporter (SERT); sodium channel (site 2); 
vasopressin V1A; progesterone (PR-B). The most significant inhibitory effect of ICG-
pHLIP was observed on progesterone B and was followed by an additional study to 
identify IC50 values, which were determined by a non-linear least square regression 
analysis using MathIQTM (ID Business Solutions Ltd., UK). The Ki values were 
calculated by the equation from Cheng and Prusoff [Cheng, Y., Prusoff, W.H., 
Biochem. Pharmacol. 22:3099-3108, 1973] using the observed IC50 of ICG-pHLIP, 
the concentration of radioligand employed in the assay, and the historical values for 
the KD of the ligand (Eurofins Panlabs data). The Hill coefficient (nH), defining the 
slope of the competitive binding curve, was calculated using MathIQTM. The IC50, Ki, 
and nH values were established for ICG-pHLIP and compared to the known 
progesterone agonist, R-2050 (Figure S3).  
 
Pharmacology and Toxicology Studies 
Pharmacology and toxicology studies were performed at the Memorial Sloan Kettering 




Labs (CRL) under approved animal protocols. The minimum human dose (h.d.) of 
ICG-pHLIP is 0.04 mg/kg. All doses of ICG-pHLIP used in pharmacology and 
toxicology studies were calculated based on the minimum h.d.  
Pharmacokinetics of ICG-pHLIP in the Beagle dogs following a single i.v. bolus 
injection 
The objective of this study performed at CRL was to characterize the pharmacokinetic 
profile of ICG-pHLIP in the Beagle dogs following a single i.v. injection. 






















0.072 0.064 2.5 0.025 3 
a  achieved dose levels calculated based on 87.7% mean recovery results from 
formulation analysis.  
Blood samples were collected at 5, 15, and 30 minutes, and 1, 2, 4, 6, 8, 12, 24, and 48 
hours post-dose for pharmacokinetic evaluation. Samples were placed on crushed wet 
ice until centrifugation, which was carried immediately. The samples were centrifuged 
as per standard procedures. An aliquot of 250 µL of the resultant plasma was separated, 
transferred to 2.0 mL low-bind tubes containing 1.25 mL of methanol, mixed and 
frozen immediately over dry ice and transferred to a freezer at -80°C. At the time of 
analysis, samples were thawed, extracted, and analyzed via LC-MS/MS according to 
the validated protocol using pHLIPIS.  
In conclusion, the administration of a single dose of ICG-pHLIP by i.v. bolus injection 




exposure to ICG-pHLIP was observed in all animals and was quantifiable up to 8 or 
12 hours post-dose.  The mean C0 (theoretical concentration at time zero following a 
bolus dose administration), AUC0-48hr (area under the concentration-time curve from 
time zero to 48hrs) and AUCINF (area under the concentration-time curve from time 




Pharmacokinetic testing of ICG-pHLIP in mice  
The purpose of this study, performed at MSKCC, was to determine the 
pharmacokinetic parameters of ICG-pHLIP in 3 female B6D2F1 mice following a 
single i.v. injection of ICG-pHLIP at a dose of 12.3 mg/kg. Blood was collected in 
EDTA tubes at 5, 15, 30 minutes, and 1, 2, 4, 6, 8, 16, and 24 hours post-injection, 
,followed by centrifugation to separate the plasma, and flash frozen. At time of 
analysis, samples were thawed, extracted, and analyzed via LC-MS as per the validated 
protocol using pHLIPIS. 
In conclusion, administration of a single dose of ICG-pHLIP by i.v. bolus injection 
was well tolerated in mice at a dose level of 12.3 mg/kg.  Evidence of systemic 
exposure to ICG-pHLIP was observed in all animals and was quantifiable up to 16 
hours post-dose.   
 
Single i.v. toxicity with acute (24 hrs) and delayed (14 days) necropsy and TK in 
Beagle dogs;  
7-days repeat i.v. toxicity in dog with acute (24h after last injection) and TK on days 




The objectives of this GLP study, performed at CRL, were to determine the potential 
toxicity of ICG-pHLIP, when given by single dose i.v. injection or once daily (i.v. 
injections) for 7 days in dogs, and to evaluate the potential reversibility of any findings 
following the single dose injection. In addition, toxicokinetic characteristics of ICG-
pHLIP were examined. 
 










































2.16**** 2.5 0.864 3 3 2 2 




2.16 2.5 0.864 2 2 - - 




** based on dose formulation analytical results, animals from Group 2  received a 
dose level of 0.063 mg/kg, which is equivalent to 0.875x h.d.  
***  equivalent to 15x h.d. 
****   equivalent to 30x h.d. 
The following parameters and end points were evaluated in the study: mortality , 
clinical observations, body weights, food consumption, ophthalmology and 
electrocardiology assessments, clinical pathology parameters (hematology, 
coagulation, clinical chemistry, and urinalysis), toxicokinetic parameters, gross 
necropsy findings, organ weights, and histopathological examinations.  
There were no unscheduled deaths.  There were no ICG-pHLIP-related clinical 
observations, and no ICG-pHLIP-related effects on the assessment of body weights, 
food consumption, ophthalmology and electrocardiology changes, hematology, 
coagulation, and urinalysis parameters, organ weights, or macroscopic and 
microscopic evaluations at any dose level tested following a single dose or a daily 7-
day repeat dose administration.  
Administration of ICG-pHLIP to dogs when given by repeated i.v. injection at 
2.16 mg/kg/day for 7 days resulted in non-adverse clinical chemistry changes limited 
to minimal decreases in cholesterol in both males and females. 
Systemic exposure to ICG pHLIP appeared to be independent of sex. Following a 
single i.v. bolus administration of ICG-pHLIP, mean C0 and AUCTlast values increased 
with increasing dose in an approximately dose proportional manner from 1.08 to 2.16 
mg/kg. Following daily i.v. bolus administration of 2.16 mg/kg ICG-pHLIP, mean C0 
and AUCTlast values were 38,400 ng/mL and 65,400 hr*ng/mL, respectively, on Day 1 




exposure (AUCTlast) to ICG-pHLIP did not appear to increase following repeated IV 
bolus administration of 2.16 mg/kg ICG-pHLIP. 
In conclusion, ICG-pHLIP administered by a single i.v. bolus injection at 0.063, 
1.08, or 2.16 mg/kg or once daily for 7 days at 2.16 mg/kg/day to dogs did not 
adversely affect overall health or condition of the animals, and had no impact on 
clinical pathology parameters, organ weights, macroscopic or microscopic pathology.  
Decreases in cholesterol levels were noted in ICG-pHLIP-treated animals at 2.16 
mg/kg/day after repeated dosing but were considered non-adverse. Based on these 
results, the no-observed-adverse-effect level (NOAEL) was considered to be 
2.16 mg/kg/day, with a Day 1 mean Cmax of 40,300 ng/ml and AUC0-24 of 
322,000 hr*ng/ml in males and females combined.   
 
7-day repeat i.v. toxicity in mice with acute (24 hrs after last injection) and delayed 
(14 days) necropsy and TK on days 1 and 7 in B6D2F1 mice  
The purpose of this GLP study performed at MSKCC was to assess the acute and 
delayed toxicity of a repeat administration of ICG-pHLIP in mice. The ICG-pHLIP 
was administered for 7 consecutive days.  









Sex Sacrifice Necropsy 
Interim sacrifice on Days 8 and 9 
1 Vehicle* 0 10 Male 







3 Vehicle 0 10 Male 




Final sacrifice on Days 21 and 22 







7 Vehicle 0 5 Male 












11 Vehicle 0 3 Male 




* 5% (vol/vol) EtOH in PBS, pH 7.4  
** equivalent to 27.6x h.d. 
Throughout the study, body weights, clinical signs, clinical pathology (hematology 
and clinical chemistry), and histopathology were collected. 
In conclusion, the repeat administration of ICG-pHLIP may be associated with germ 
cell degeneration in males with incidence and severity decreasing over time. No other 





Follow up 7-days repeat i.v. toxicity in male mice with acute (24 hrs after last 
injection) and delayed (14 days) necropsy and TK on days 1 and 7 in B6D2F1 mice  
The purpose of this GLP study performed at MSKCC was to assess the acute and 
delayed toxicity on the male reproductive system of mice of a repeat administration of 
ICG-pHLIP at different concentrations. The ICG-pHLIP was administered once/day 
for 7 consecutive days.  
















Interim sacrifice on Day 8 
1 Vehicle* 0 10 













Final sacrifice on Day 21 
5 Vehicle 0 5 
















9 Vehicle 0 3 













* 5% (vol/vol) EtOH in PBS, pH 7.4 
** equivalent to 10x h.d. 
***  equivalent to 15x h.d. 
****  equivalent to 25x h.d. 
Throughout the study, body weights, clinical signs, and histopathology were collected.  
In conclusion, the repeat administration of ICG-pHLIP at all dose levels is well 
tolerated, with no indication of germ cell degeneration or other toxicity to the male 
reproductive system. 
 
Local tolerance/irritancy in New Zealand white rabbits 
The objective of this GLP study performed at CRL was to compare the i.v., intra-
arterial, perivascular and subcutaneous routes for potential irritation following a single 












































1.86*** 5.58 3 0.62 5.58 3 
 


















































































































0.62 5.735 3 
i.a. = intra-arterial; i.v. = intravenous; subc. = subcutaneous. 
* 5% (vol/vol) EtOH in PBS, pH 7.4 
** equivalent to 1x h.d.; based on dose formulation analytical results, animals from 
Group 2 and 5 received a dose level of 0.109 mg/kg for i.v.,i.a. and/or subc. injection 
and 0.009 mg for perivenous space injection. 
***  equivalent to 15x h.d. 
The following parameters and end points were evaluated in this study:  clinical signs, 
local irritation assessment, body weights (for dose calculation only), and 
histopathology of the injection sites. There were no clinical signs, local irritation or 
any microscopic changes associated with ICG-pHLIP during the study. 
In conclusion, a single administration of ICG-pHLIP via i.v., intra-arterial, perivenous 
and subcutaneous injection was well tolerated in rabbits at total dose levels of 0.124 






A pharmacological safety assessment on the central nervous system of the Sprague 
Dawley rats  
The objective of this GLP study performed at CRL was to evaluate the 
pharmacological effects of ICG-pHLIP on the central nervous system following a 
single i.v. bolus injection in rats. 
































7.44***** 5 1.488 8 
* 5% (vol/vol) EtOH in PBS, pH 7.4  
** equivalent to 0.88x h.d. 
***  equivalent to 1x h.d. 
**** equivalent to 15x h.d. 
*****  equivalent to 30x h.d. 
Functional observation battery (FOB) tests were performed once prior to dosing and 




palpebral closure, eye prominence, pupil size, pupillary response, lacrimation, 
salivation, body tone, extensor thrust, pinna reflex, tactile reflex, overall animal 
reactivity, auricular startle, air righting reflex, body temperature (rectal).  Additional 
evaluations consisted of mortality and clinical observations.  
There were no ICG-pHLIP -related changes on any qualitative or quantitative FOB 
parameters at 0.218, 0.248, 3.72 and 7.44 mg/kg up to 24 hours post-dose. 
In conclusion, a single i.v. bolus administration of ICG-pHLIP at dose levels of 0.218, 
0.248, 3.72 and 7.44 mg/kg to rats had no effect on the central nervous system up to 
24 hours post-dose. 
 
A cardiovascular telemetry study in unrestrained conscious non-naïve Beagle dogs 
The objective of this GLP study performed at CRL was to evaluate the potential 
cardiovascular effects of ICG-pHLIP in instrumented dogs when administered by i.v. 
bolus injection using a Latin square design. 
Each of the four male dogs received a dose of Reference Item (5 % Ethanol in 
Phosphate buffered saline (PBS), pH of 7.4 ± 0.2) and three dose levels of ICG-pHLIP 
(0.072, 0.36, and 1.44 mg/kg), with a 7-day washout period between each dose. The 
dose was administered by i.v. bolus injection  at a dose volume of 2.5 mL/kg. 
The study design was as follows (16 male Beagle dogs): 
Dosing Schedule (mg/kg) 
Animal 
No. 
Dose 1 Dose 2 Dose 3 Dose 4 
1 0 0.072 1.44 0.36 
2 0.072* 0.36 0 1.44 














0 0 2.5 4 
0.072 0.029 2.5 4 
0.36 0.144 2.5 4 
1.44 0.576 2.5 4 
* equivalent to 1x h.d. 
**  equivalent to 5x h.d. 
*** equivalent to 20x h.d. 
The following cardiovascular parameters were evaluated for all animals from 2 hours 
prior and up to 24 hours post each dose:  systemic blood pressures (systolic, diastolic, 
mean arterial, and pulse pressure), heart rate, body temperature, and 
electrocardiographic duration/intervals (PR, QRS, QT, and QTc).  Qualitative 
evaluation of the electrocardiographic waveforms was performed twice prior to each 
dose (at least 30 minutes apart) and at 5, 15, and 30 minutes, 1, 2, 3, 4, 6, 12, and 24 
hours post-dose. Additional evaluations consisted of mortality and clinical 
observations. There were no mortalities or ICG-pHLIP-related clinical signs 
throughout the course of the study.  
In conclusion, a single i.v. bolus injection of ICG-pHLIP at 0.072, 0.36, and 
1.44 mg/kg to male dogs resulted in no effect on systemic blood pressures, heart rate, 
body temperature, electrocardiographic intervals (PR, QRS, QT or heart rate corrected 





Micronucleus test in Sprague Dawley rats  
The objective of this GLP study performed at CRL was to determine the potential 
genotoxicity of ICG-pHLIP when given by i.v. bolus injection to rats using the 
peripheral blood micronucleus test.  
In order to determine the maximum tolerated dose, a dose-range finding test was 
performed prior to the main test, where male and female rats (3 animals/sex) were 
administered a single dose of ICG-pHLIP by i.v. injection.  The doses evaluated were 
14 mg/kg and 25 mg/kg using 5% EtOH in PBS, pH 7.4 as the vehicle.  Animals were 
observed for signs of toxicity and/or mortality.  As no adverse clinical signs were noted 
during the dose-range finding test, the maximum practical dose of 25 mg/kg was set 
as the high dose to be evaluated in the main test using a single sex (males).   











No. of Animals 
Male Female 
1 ICG-pHLIP 14*** 10 1.4 3 3 
2 ICG-pHLIP 25**** 10 2.5 3 3 




4 ICG-pHLIP 6.25* 10 0.625 5 - 
5 ICG-pHLIP 12.5** 10 1.25 5 - 
6 ICG-pHLIP 25 10 2.5 5 - 
7 CP****** 10 10 1 5 - 
* equivalent to 25x h.d.   
** equivalent to 50x h.d.   
*** equivalent to 56x h.d.   
**** equivalent to 100x h.d. – the maximum practical dose of ICG-pHLIP 
***** NC is the negative control, 5% EtOH in PBS, pH 7.4.   
****** PC is the positive control, cyclophosphamide monohydrate. Animals were 




Analysis of ICG-pHLIP dosing formulations conducted during the study confirmed 
that all formulations were acceptable for use.  
No mortalities occurred during the main test and no ICG-pHLIP-related adverse 
clinical signs were observed.  Additionally, no ICG-pHLIP-related body weight loss 
or depression in body weight gains were observed.   
Blood was collected for micronuclei evaluation at 45 hours post-dose (Groups 3 to 7), 
and 69 hours post-dose (Groups 3 and 7).  The proportion of immature erythrocytes 
among total erythrocytes in the peripheral blood (%RETs) and the percentage of 
micronucleated reticulocytes (%MN-RETs) in the NC group were within the 
laboratory historical negative control range. A clear, unequivocal and statistically 
significant increase in micronuclei was observed in the PC group.  The results from 
both NC and PC groups confirmed the validity of the assay.  
No substantial reduction (i.e. less than 50% the value of the concurrent NC) in the 
%RETs was observed for any of the ICG-pHLIP dosed groups, indicating that no 
substantial cytotoxicity was observed.  Animals dosed with ICG-pHLIP did not show 
any statistically significant increases in the %MN-RETs when compared to the 
concurrent NC group.  Therefore, ICG-pHLIP did not induce cytogenetic damage in 
peripheral blood immature erythrocytes in this micronucleus test, when administered 
once, by i.v. injection to male rats, up to the maximum practical dose of 25  mg/kg. 
In conclusion, ICG-pHLIP showed no evidence of genotoxic activity in this in vivo 






In vitro bacterial reverse mutation test 
The objective of this study performed at CRL was to determine the potential 
genotoxicity of ICG-pHLIP using the bacterial reverse mutation test.  











No. of Replicates 
No. of 





- 3 3 5 
1/ ICG-pHLIP 500 3.16 1.58 3 3 5 
1/ ICG-pHLIP 500 10 5.0 3 3 5 
1/ ICG-pHLIP 500 31.6 15.8 3 3 5 
1/ ICG-pHLIP 500 100 50 3 3 5 
2/ ICG-pHLIP 1581 100 158 3 3 5 
3/ ICG-pHLIP 5000 100 500 3 3 5 
4/ ICG-pHLIP 15811 100 1581 3 3 5 





*** 3 3 5 
* vehicle, dimethyl sulfoxide (DMSO), was used as a negative control  
** the OECD/ICH S2(R1) standard limit dose (usually 5000 µg/plate).   
*** dose depended on the test strain, the positive controls and methodology used.  
Salmonella typhimurium strains (TA1535, TA1537, TA98, TA100 and TA102) were 
treated with ICG-pHLIP at a range of concentrations up to 5000 µg/plate (the standard 




fraction (S9 mix), using the plate incorporation version of the bacterial reverse 
mutation test.  
Bacteria were incubated with standard positive controls, and the response of the 
various bacterial strains to these agents confirmed the sensitivity of the test system and 
the activity of the S9 mix.   
Incomplete, or absent, background lawns of non-revertant bacteria, or substantial 
reductions in revertant colony counts, were not obtained following exposure to ICG-
pHLIP, indicating that ICG-pHLIP was non-toxic to the bacteria at the levels tested.  
No precipitation was observed in the assay.  
No substantial increases in revertant colony numbers were obtained with any of the 
tester strains, following exposure to ICG-pHLIP at any dose level, in either the 
presence or absence of S9 mix.  Therefore, ICG-PHLIP was considered to be negative 
for the induction of mutagenicity in this in vitro assay. 
In conclusion, ICG-pHLIP did not show any evidence of genotoxic activity in this in 




In vitro micronucleus test   
The objective of this study performed at CRL was to determine the potential 
genotoxicity of ICG-pHLIP using an in vitro mammalian cell micronucleus test in 
human peripheral blood lymphocytes. 























- 50 - 2 2 2 
1/ ICG-pHLIP 500 10 1.00 2 2 2 
1/ ICG-pHLIP 500 20 2.00 2 2 2 
1/ ICG-pHLIP 500 40 4.00 2 2 2 
2/ ICG-pHLIP 800 50 8.00 2 2 2 
3/ ICG-pHLIP 1600 50 16.0 2 2 2 
4/ ICG-pHLIP 3200 50 32.0 2 2 2 
5/ ICG-pHLIP 6400 50 64.0 2 2 2 
6/ ICG-pHLIP 12800 50 128 2 2 2 
7/ ICG-pHLIP 25600 50 256 2 2 2 
8/ ICG-pHLIP 50000 50 500** 2 2 2 
Colcemid 
10 80 0.16 2 - - 
10 90 0.18 2 - - 
10 100 0.20 2 - - 
Nocodazole 
20 50 0.20 2 - - 
25 50 0.25 2 - - 
30 50 0.30 2 - - 
Cyclophospha
mide 
1000 50 10 - 2 - 
1500 50 15 - 2 - 





















20 50 0.20 - - 2 
* vehicle, dimethyl sulfoxide (DMSO), was used as a negative control  
**     where the high level = 0.5 mg/mL.  
Human peripheral blood lymphocytes were treated with ICG-pHLIP at levels up to the 
standard limit of 0.5 mg/mL. The high dose for micronucleus assessment was 0.5 
mg/mL as no ICG-pHLIP-related cytotoxicity or precipitation was observed in the 
assay.  The Negative Control results were within the laboratory negative historical 
control range.  Lymphocytes were also incubated with standard Positive Controls, 
which caused statistically significant increases in the proportion of cells with 
micronuclei, confirming the sensitivity of the test system and the activity of 
the S9 mix.  All criteria for a valid assay were therefore met. 
Cultures treated with ICG-pHLIP did not show any statistically significant increases 
in the incidence of micronucleated binucleate cells. All results were within the 
distribution of the laboratory historical negative control data. Therefore, ICG-pHLIP 
was considered to be negative for the induction of micronuclei in this in vitro assay. 
In conclusion, ICG-pHLIP did not show any evidence of genotoxic activity in the 
in vitro micronucleus test in human peripheral blood lymphocytes, when tested in 
accordance with regulatory guidelines. 
 
Animal Imaging Studies 
All imaging studies on mice were conducted at University of Rhode Island according 




procedures outlined by the National Institutes of Health for the care and use of animals. 
All imaging studies in pigs were conducted at the Porcine Laboratory, Sutter Institute 
for Medical Research and approved animal protocol STE.10.19 (Stryker Endoscopy 
Imaging and Instrumentation Studies). 
 
Imaging of Blood Vessels in Mice 
ICG-malemide was conjugated with Cys to form ICG-Cys for use as a control. Single 
tail vein administrations of 2.5 nmol of ICG-Cys or ICG-pHLIP in sterile PBS  or PBS 
with 5% DMSO or 5% Ethanol (vol:vol) (volume of the injection was 100 μl) were 
given to athymic female nude mice (strain Hsd Athymic Nude-Foxn1nu) ranging in 
age from 5 to 6 weeks (obtained from Envigo RMS Inc). Mice were under gas 
anesthesia, and imaging of mouse leg and ear was performed immediately and at 
different time points (from 5 min till 120 min) after administration of ICG-Cys or ICG-
pHLIP using the Stryker 1558 AIM clinical imaging system with L10 AIM Light 
Source, 1588 AIM Camera and a 10 mm scope and a Novadaq imaging system. Five 
animals per construct were used in the study.  
 
Imaging of Blood Vessels in Pigs 
Pigs (50 kg) received ICG-pHLIP dissolved in PBS or PBS containing 5% Ethanol. 
Three doses of pHLIP-ICG were administered (dose level 1 is 0.052 mg/kg of ICG-
pHLIP, dose level 2 is an additional administration of 0.12 mg/kg of ICG-pHLIP and 
dose level 3 is an additional administration of 0.24 mg/kg of ICG-pHLIP). Each dose 
was injected intravenously in one bolus followed by a saline flush. Endoscopical and 
exoscopical imaging was performed at the same time and up to 2 hrs after ICG-pHLIP 
administration. Imaging endoscopically was carried out using the Stryker 1688 system 




Stryker AIM laparoscope was used for imaging of animal internal cavities. Open field 
imaging was performed using the Stryker SPY-PHI system (805 nm excitation) and 
fixed gain. Images and video were recorded on a Stryker Connected OR Hub device. 
The 1688 system has three infrared imaging modes: Overlay, Contrast, and ENV. 
Overlay mode captures an NIR frame and a white light frame and combines the two to 
allow surgeons to have the best fluorescence reference (green) while still operating. 
Contrast mode provides the highest signal to noise image for the fluorescence signal 
and does not contain any data from the white light frame. ENV mode contains the 
white light frame data in a black/white mode and overlays the fluorescence signal in 
green to provide a hybrid mode that allows a higher signal to noise ratio view of the 
fluorescence image while still retaining enough of a view of the surrounding tissue to 
allow the surgeon to continue to operate. The SPY-PHI system has three infrared 
imaging modes: Overlay, Contrast, and CSF (color-segmented fluorescence). CSF 
mode is a type of heat map where the fluorescence signal is mapped to color according 
to intensity. Contrast mode is noticeably more sensitive to viewers than Overlay or 
CSF mode for weaker signals. 
 
Biodistribution and Kinetics  
BALB/cAcNHsd mice ranging in age from 5 to 6 weeks obtained from Envigo RMS, 
Inc. were used in the study. Mouse mammary 4T1 cancer cells were subcutaneously 
implanted in the right flank (8 x 105 cells/0.1 mL/flank) of adult female or male mice. 
The triple negative 4T1 tumor model closely mimics stage IV of human breast cancer. 
When tumors reached 5-6 mm in diameter, single tail vein injections of 0.5 mg/kg of 
ICG-pHLIP in sterile PBS, or PBS with 5% DMSO or 5% Ethanol (vol:vol) (volume 
of the injection was 100 μl) were performed. Animals were euthanized at time points: 




were used for each time point plus seven control animals (no ICG-pHLIP 
administration). Tumor, muscles, skin, heart, lungs, liver, spleen, kidneys, brain, 
pancreas, bone, stomach, small and large intestines were collected, imaged 
immediately after necropsy, weighed, and fast frozen in liquid nitrogen. The ex vivo 
imaging of organs was performed using Stryker 1588 AIM endoscopic system with 
L10 AIM Light Source, 1588 AIM Camera using a 10 mm scope. The lens was spaced 
4.3 cm away from the surface of the organs within an enclosed (light protected) area. 
The NIR fluorescence imaging of each organ was performed at three different laser 
intensity settings. The digital images of organs were processed using aour program 
written in Python to determine the average level of intensity recorded in the green 
channel. Since organs were imaged in the dark on black mats, the background signal 
was determined by introducing an intensity threshold. All the pixels with intensity 
from the green channel above the set threshold were counted and the average green 
intensity per pixel was calculated. For organs for which the highest laser intensity 
produced a saturated image, the medium laser intensity images were analyzed, then 
converted to a theoretical comparison using experimentally found conversion curves.  
The fluorescence signals in organs and tissue were also measured in the tissue/organ 
homogenates and compared with the signals from the control tissue/organ 
homogenates (collected from control mice) mixed with known amounts of ICG-
pHLIP. About 100 mg of tissue were homogenized with 2.5x (about 250 µL) volumes 
of DMSO using BioMasher II disposable homogenizers (DiagnoCine, LLC). 30 µl of 
homogenate was placed into 384 well plate and imaged using an Odyssey IR scanner 
(Li-Cor Biosciences). Tissue homogenates of control mice mixed with known 





Imaging Tumors iin Different Tumor Models 
Targeting of murine and human tumors was shown in 8 different tumor models in 
athymic female nude mice (strain Hsd Athymic Nude-Foxn1nu) ranging in age from 5 
to 6 weeks (obtained from Envigo RMS, Inc). The following tumors were established 
by subcutaneous injection of 1 x 106 cells/0.1 ml/flank in flanks of athymic nude mice: 
HeLa (humans cervical adenocarcinoma), M4A4 (human epithelial carcinoma), 4T1 
(murine breast tumor), A549 (human lung carcinoma), LLC (murine Lewis Lung 
carcinoma), UM-UC3 (human urinary bladder cancer), and 4 x 106 cells/0.1 ml/flank 
of LNCaP tumor (human prostate cancer). Human MDA-MB-231 (breast 
adenocarcinoma) tumors were established by injections of 1 x 10 6 cells/0.05 ml in the 
mammary fat pad. Tumors reached different sizes (from very small (1 -2 mm in 
diameter) to large (8-12 mm in diameter) and 100 μl of tail vein injections of 0.5 mg/kg 
of ICG-pHLIP in sterile PBS or PBS containing either 5% of DMSO or 5% of Ethanol 
were performed. Imaging was carried at 24 hours after ICG-pHLIP administration. 
White light and NIR whole-body imaging were performed while the animal was under 
gas (isoflurane) anesthesia using a Stryker 1558 AIM clinical imaging system with 
L10 AIM Light Source, 1588 AIM Camera and a 10 mm scope. Next, the skin was 
removed from the tumor side and whole-body imaging of live animals was performed 
with the skin removed from the tumor side. Finally, surgery was carried out under 
fluorescence-guidance to remove tumor and image tumor bed using Stryker SPY-PHI 
handheld clinical imaging system. 
 
Histopathology 
Tumors with surrounding muscle were frozen in tissue-tek OCT compound using 




Scientific HM525 NX) at a 5 µm thickness. The tumor slides were fixed in 4% 
formaldehyde and stained with hematoxylin and eosin (H&E) (Thermo Fisher 
Scientific and Poly Scientific R & D Corp). Some sections were covered with a drop 
of mounting medium (Permount®, Fisher Scientific) and then a cover slide was placed 
over the medium. Stained and non-stained sections were imaged using an Odyssey IR 
scanner (Li-Cor Biosciences), Styker imaging system, and inverted microscope 
"Invitrogen EVOS FL Auto 2" using 4x and 10x objectives. Tiled HE images were 








Table S1. Qualification of GLP ICG-pHLIP verification batch #1912127 










1382.9 [M+3H]3+/3 ± 1 amu conforms 
Identity HPLC 
Elution peak with 5% 
deviation 
conforms 
Purity, (p) HPLC >98.5% 98.6% 
Impurities HPLC Total Imp.: NMT 1.5% 1.4% 
Acetic Acid Content IC  5% 4.4% 
TFA Content IC Determine and report 0.01% 
Photo-Assay NIR 0.8 ∙ 𝑝 ∙ 𝑘  OD  1.11 ∙ 𝑝 ∙ 𝑘  0.85 
Residual solvents  GC Determine and report 
DMF < 100 
ppm 




MTBE < 50 
ppm 
DCM < 50 
ppm 
Water content KF Determine and report 1.55% 












Cation Content, Na+ IC Determine and report <0.01% 
Peptide Content/Amino 
Acid Composition 




Conforms to theory 
Conforms to 
theory, 
beside AA 1 
and 2 
LC-MS - liquid chromatography - mass spectrometry; HPLC - high performance liquid 
chromatography; IC – ion chromatography; GC – gas chromatography; KF - Karl-
Fischer titration; CHN – carbon, hydrogen, nitrogen element analysis;  AAA – amino 






























Human >99.9% >99.9% <0.1% 
Mouse >99.9% 95.3% 4.8% 
Rat >99.9% 96.6% 2.3% 
Dog >99.9% 98.8% 1.2% 
Minipig >99.9% 99.3% 0.7% 
Cyno >99.9% 99.6% 0.4% 




Table S3. Concentration of ICG-pHLIP (µg/mL) in blood of mice and dogs at different 
time points after single i.v. administration of 12.3 mg/kg of ICG-pHLIP to mice and 




pHLIP in mice blood, 
µg/mL 
Concentration of ICG-












1.347 ± 0.092 
1.230 ± 0.082 
1.123 ± 0.089 
0.882 ± 0.099 
0.749 ± 0.065 
0.432 ± 0.056 
0.319 ± 0.041 
0.207 ± 0.032 
0.118 ± 0.008 
- 
275.4 ± 7.5 
251.5 ± 13.9 
239.8 ± 6.3 
217.0 ± 8.9 
144.0 ± 13.1 
102.6 ± 4.8 
68.7 ± 1.3 
58.8 ± 14.0 
- 






Table S4. Fluorescence intensity (a.u.) obtained by ex vivo imaging of organs collected 
at different time points after i.v. administration of ICG-pHLIP into female Balb/C mice 
bearing 4T1 tumors in right flank. 





























































































































































































































































































































































































































































































































































































































































Table S5. Mean (and St. D.) of fluorescence intensity values presented in Table S4.  
Organ/
Time  

























































































































































































































































Figure S1. (a) HPLC chromatogram of ICG-pHLIP used in PoC and toxicology 
studies. (b) The spiking experiment: ICG-pHLIP synthesized by CordenPharma 
according to the optimized protocol was spiked with ICG-pHLIP shown on panel a in 
ratio of 1:1, dissolved in ACN/water/Tween20 in a ratio of 50:50:0.02 containing 5 
mM tri potassium-EDTA and analyzed using the standard analytical method. The 
HPLC chromatogram provides a single signal, consistent with the compliance of both 








Figure S2. Normalized absorbance spectrum of ICG-pHLIP in methanol (a), 
absorbance and fluorescence spectra of Isosulfan Blue (IB) in water, Methylene Blue 
(MB) in PBS, and absorbance spectra of ICG-pHLIP (ICG) in DMSO (b). Color image 
of mouse received intra-tumoral injection of Isosulfan Blue (c). NIRF image of the 
same mouse followed by intra-tumoral injection of ICG-pHLIP (d). Overlay of color 
and NIRF ICG-pHLIP images (e) and color image of the same mouse after 
administration of both IB and ICG-pHLIP (f). The data clearly demonstrate that the 








Figure S3. Inhibition response curves obtained in a radio ligand binding assay after 
treatment of progesterone B with increasing concentrations of ICG-pHLIP and R-5020 
(a known progesterone B agonist) for 20 hrs. The experiments were performed by 











Figure S4. Fluorescence angiography with ICG-pHLIP. Mice under gas anesthesia 
received a single tail vein injection of 0.5 mg/kg of ICG-pHLIP followed by imaging 
within 2 hrs using a Novadaq imaging system. The signal was recorded from the mouse 








Figure S5. Imaging of blood vessels in pigs. NIR ICG-pHLIP fluorescent images of 
blood vessels at different time points after a single i.v. injection of ICG-pHLIP are 
shown. Imaging inside the pig body cavity was performed using a Stryker system for 
endoscopic/laparoscopic imaging (a). Imaging of a pedicle flap was performed using 








Figure S6. Photo image of Balb/C mouse bearing 4T1 tumors in both flanks (a-b) or 
in a single flank (c-d) with skin removed from the tumor site (a, c). Overlays of photo 
and NIR ICG-pHLIP fluorescent images are shown (b, d) (tumors are indicated by 
arrows). ICG-pHLIP was administrated as a single i.v. injection (0.5 mg/kg), imaging 
was performed 24 hrs post-dose while animal was under gas anesthesia and was 









Figure S7. Tissue/organ mean surface fluorescence calculated from NIR ICG-pHLIP 
fluorescent images for each mouse (the representative images are shown on Figure 4 
and numbers are given in Table S4) and the calculated mean values o f fluorescence 







Figure S8. Photo images and overlay of photo and NIR ICG-pHLIP fluorescent 
images of athymic nude mice bearing human and murine tumors. ICG-pHLIP was 
administrated as a single i.v. injection (0.5 mg/kg), imaging was performed 24 hrs post-








Figure S9. Each row contains an HE image, a NIR ICG-pHLIP fluorescent image, and 
an overlay of HE and NIR ICG-pHLIP images. UMUC3 human urinary transitional 
carcinoma (a) and 4T1 murine mammary cancer (b) tumors were grown in flanks of 
nude mice. ICG-pHLIP was administrated as a single i.v. injection (0.5 mg/kg) . 
Animals were euthanized 24 hrs post-dose, tumors were collected, frozen, and cryo-
sectioned. Each second section was stained with HE. HE sections were imaged using 
a Stryker instrument and NIR imaging was performed using an Odyssey IR scanner. 
The correlation between tumor location (dark blue) and fluorescent signal is 
demonstrated. 
 
 
